

Supplement table S1. The cumulative incidence rates of non-fatal immune-related adverse events stratified by gender

| Disease | Gender | Vaccination | total | One week | | | | Two weeks | | | | One month | | | | Three months | | | |
|---------------------|--------|-------------|--------|----------|------|-----------|--------|-----------|-------|-------------|--------|-----------|-------|-------------|--------|--------------|-------|-------------|--------|
| | | | | event | IR | 95% CI | P | event | IR | 95% CI | P | event | IR | 95% CI | P | event | IR | 95% CI | P |
| Endometriosis | Male | No | 143128 | | | | | | | | | | | | | | | | |
| | | Yes | 718173 | | | | | | | | | | | | | | | | |
| | Female | No | 146448 | 4 | 0.27 | 0.01-0.54 | 0.389 | 13 | 0.89 | 0.41-1.37 | 0.877 | 35 | 2.39 | 1.60-3.18 | 0.703 | 99 | 6.76 | 5.43-8.09 | 0.164 |
| | | Yes | 740384 | 34 | 0.46 | 0.30-0.61 | | 63 | 0.85 | 0.64-1.06 | | 165 | 2.23 | 1.89-2.57 | | 584 | 7.89 | 7.25-8.53 | |
| Menstrual disorder | Male | No | 143128 | | | | | | | | | | | | | | | | |
| | | Yes | 718173 | | | | | | | | | | | | | | | | |
| | Female | No | 146448 | 82 | 5.6 | 4.39-6.81 | 0.638 | 161 | 10.99 | 9.30-12.69 | 0.112 | 346 | 23.63 | 21.14-26.11 | 0.003 | 1025 | 69.99 | 65.72-74.26 | <0.001 |
| | | Yes | 740384 | 442 | 5.97 | 5.41-6.53 | | 935 | 12.63 | 11.82-13.44 | | 2081 | 28.11 | 26.90-29.31 | | 6481 | 87.54 | 85.41-89.66 | |
| Bruise | Male | No | 143128 | 1 | 0.07 | 0.00-0.21 | 0.007 | 2 | 0.14 | 0.00-0.33 | 0.001 | 3 | 0.21 | 0.00-0.45 | <0.001 | 17 | 1.19 | 0.62-1.75 | <0.001 |
| | | Yes | 718173 | 42 | 0.58 | 0.41-0.76 | | 65 | 0.91 | 0.69-1.13 | | 108 | 1.5 | 1.22-1.79 | | 218 | 3.04 | 2.63-3.44 | |
| | Female | No | 146448 | 3 | 0.2 | 0.00-0.44 | 0.005 | 4 | 0.27 | 0.01-0.54 | <0.001 | 8 | 0.55 | 0.17-0.92 | <0.001 | 31 | 2.12 | 1.37-2.86 | <0.001 |
| | | Yes | 740384 | 65 | 0.88 | 0.66-1.09 | | 116 | 1.57 | 1.28-1.85 | | 179 | 2.42 | 2.06-2.77 | | 341 | 4.61 | 4.12-5.09 | |
| Herpes zoster | Male | No | 143128 | 8 | 0.56 | 0.17-0.95 | <0.001 | 21 | 1.47 | 0.84-2.09 | <0.001 | 59 | 4.12 | 3.07-5.17 | <0.001 | 179 | 12.51 | 10.68-14.34 | <0.001 |
| | | Yes | 718173 | 188 | 2.62 | 2.24-2.99 | | 411 | 5.72 | 5.17-6.28 | | 907 | 12.63 | 11.81-13.45 | | 2641 | 36.77 | 35.37-38.17 | |
| | Female | No | 146448 | 23 | 1.57 | 0.93-2.21 | <0.001 | 45 | 3.07 | 2.18-3.97 | <0.001 | 103 | 7.03 | 5.68-8.39 | <0.001 | 275 | 18.78 | 16.56-21.00 | <0.001 |
| | | Yes | 740384 | 284 | 3.84 | 3.39-4.28 | | 644 | 8.7 | 8.03-9.37 | | 1363 | 18.41 | 17.43-19.39 | | 3934 | 53.13 | 51.48-54.79 | |
| Alopecia | Male | No | 143128 | 2 | 0.14 | 0.00-0.33 | 0.053 | 5 | 0.35 | 0.04-0.66 | 0.047 | 11 | 0.77 | 0.31-1.22 | 0.001 | 38 | 2.65 | 1.81-3.50 | <0.001 |
| | | Yes | 718173 | 38 | 0.53 | 0.36-0.70 | | 62 | 0.86 | 0.65-1.08 | | 143 | 1.99 | 1.66-2.32 | | 373 | 5.19 | 4.67-5.72 | |
| | Female | No | 146448 | 4 | 0.27 | 0.01-0.54 | 1 | 5 | 0.34 | 0.04-0.64 | 0.064 | 12 | 0.82 | 0.36-1.28 | 0.015 | 42 | 2.87 | 2.00-3.74 | <0.001 |
| | | Yes | 740384 | 23 | 0.31 | 0.18-0.44 | | 60 | 0.81 | 0.61-1.02 | | 123 | 1.66 | 1.37-1.95 | | 393 | 5.31 | 4.78-5.83 | |
| Warts | Male | No | 143128 | 9 | 0.63 | 0.22-1.04 | 0.286 | 14 | 0.98 | 0.47-1.49 | 0.003 | 40 | 2.79 | 1.93-3.66 | <0.001 | 103 | 7.2 | 5.81-8.59 | <0.001 |
| | | Yes | 718173 | 68 | 0.95 | 0.72-1.17 | | 156 | 2.17 | 1.83-2.51 | | 349 | 4.86 | 4.35-5.37 | | 983 | 13.69 | 12.83-14.54 | |
| | Female | No | 146448 | 11 | 0.75 | 0.31-1.19 | 0.649 | 16 | 1.09 | 0.56-1.63 | 0.02 | 38 | 2.59 | 1.77-3.42 | 0.005 | 94 | 6.42 | 5.12-7.72 | <0.001 |
| | | Yes | 740384 | 67 | 0.9 | 0.69-1.12 | | 147 | 1.99 | 1.66-2.31 | | 309 | 4.17 | 3.71-4.64 | | 828 | 11.18 | 10.42-11.94 | |
| Visual impairment | Male | No | 143128 | 0 | 0 | 0.00-0.00 | 1 | 0 | 0 | 0.00-0.00 | 0.598 | 0 | 0 | 0.00-0.00 | 0.154 | 0 | 0 | 0.00-0.00 | 0.006 |
| | | Yes | 718173 | 3 | 0.04 | 0.00-0.09 | | 6 | 0.08 | 0.02-0.15 | | 15 | 0.21 | 0.10-0.31 | | 31 | 0.43 | 0.28-0.58 | |
| | Female | No | 146448 | 0 | 0 | 0.00-0.00 | 1 | 0 | 0 | 0.00-0.00 | 1 | 0 | 0 | 0.00-0.00 | 0.368 | 2 | 0.14 | 0.00-0.33 | 0.561 |
| | | Yes | 740384 | 2 | 0.03 | 0.00-0.06 | | 3 | 0.04 | 0.00-0.09 | | 8 | 0.11 | 0.03-0.18 | | 19 | 0.26 | 0.14-0.37 | |
| Glaucoma | Male | No | 143128 | 11 | 0.77 | 0.31-1.22 | <0.001 | 28 | 1.96 | 1.23-2.68 | <0.001 | 78 | 5.45 | 4.24-6.66 | <0.001 | 216 | 15.09 | 13.08-17.10 | <0.001 |
| | | Yes | 718173 | 198 | 2.76 | 2.37-3.14 | | 393 | 5.47 | 4.93-6.01 | | 849 | 11.82 | 11.03-12.62 | | 2556 | 35.59 | 34.21-36.97 | |
| | Female | No | 146448 | 32 | 2.19 | 1.43-2.94 | 0.056 | 52 | 3.55 | 2.59-4.52 | <0.001 | 121 | 8.26 | 6.79-9.73 | <0.001 | 318 | 21.71 | 19.33-24.10 | <0.001 |
| | | Yes | 740384 | 232 | 3.13 | 2.73-3.54 | | 508 | 6.86 | 6.26-7.46 | | 1043 | 14.09 | 13.23-14.94 | | 3193 | 43.13 | 41.63-44.62 | |
| Tinnitus | Male | No | 143128 | 5 | 0.35 | 0.04-0.66 | 0.197 | 12 | 0.84 | 0.36-1.31 | 0.081 | 25 | 1.75 | 1.06-2.43 | 0.001 | 73 | 5.1 | 3.93-6.27 | <0.001 |
| | | Yes | 718173 | 48 | 0.67 | 0.48-0.86 | | 105 | 1.46 | 1.18-1.74 | | 238 | 3.31 | 2.89-3.73 | | 789 | 10.99 | 10.22-11.75 | |
| | Female | No | 146448 | 6 | 0.41 | 0.08-0.74 | 0.044 | 14 | 0.96 | 0.46-1.46 | 0.025 | 29 | 1.98 | 1.26-2.70 | <0.001 | 98 | 6.69 | 5.37-8.02 | <0.001 |
| | | Yes | 740384 | 71 | 0.96 | 0.74-1.18 | | 132 | 1.78 | 1.48-2.09 | | 296 | 4 | 3.54-4.45 | | 1000 | 13.51 | 12.67-14.34 | |
| Inner ear disease | Male | No | 143128 | 13 | 0.91 | 0.41-1.40 | <0.001 | 20 | 1.4 | 0.78-2.01 | <0.001 | 48 | 3.35 | 2.41-4.30 | <0.001 | 147 | 10.27 | 8.61-11.93 | <0.001 |
| | | Yes | 718173 | 171 | 2.38 | 2.02-2.74 | | 355 | 4.94 | 4.43-5.46 | | 798 | 11.11 | 10.34-11.88 | | 2219 | 30.9 | 29.61-32.18 | |
| | Female | No | 146448 | 30 | 2.05 | 1.32-2.78 | <0.001 | 51 | 3.48 | 2.53-4.44 | <0.001 | 104 | 7.1 | 5.74-8.47 | <0.001 | 319 | 21.78 | 19.39-24.17 | <0.001 |
| | | Yes | 740384 | 382 | 5.16 | 4.64-5.68 | | 739 | 9.98 | 9.26-10.70 | | 1583 | 21.38 | 20.33-22.43 | | 4651 | 62.82 | 61.02-64.62 | |
| Middle ear disease | Male | No | 143128 | 5 | 0.35 | 0.04-0.66 | <0.001 | 15 | 1.05 | 0.52-1.58 | <0.001 | 39 | 2.72 | 1.87-3.58 | <0.001 | 126 | 8.8 | 7.27-10.34 | <0.001 |
| | | Yes | 718173 | 102 | 1.42 | 1.14-1.70 | | 217 | 3.02 | 2.62-3.42 | | 495 | 6.89 | 6.29-7.50 | | 1495 | 20.82 | 19.76-21.87 | |
| | Female | No | 146448 | 9 | 0.61 | 0.21-1.02 | 0.004 | 27 | 1.84 | 1.15-2.54 | 0.002 | 54 | 3.69 | 2.70-4.67 | <0.001 | 164 | 11.2 | 9.49-12.91 | <0.001 |
| | | Yes | 740384 | 116 | 1.57 | 1.28-1.85 | | 251 | 3.39 | 2.97-3.81 | | 563 | 7.6 | 6.98-8.23 | | 1848 | 24.96 | 23.82-26.10 | |
| Other ear disease | Male | No | 143128 | 19 | 1.33 | 0.73-1.92 | <0.001 | 32 | 2.24 | 1.46-3.01 | <0.001 | 84 | 5.87 | 4.61-7.12 | <0.001 | 267 | 18.65 | 16.42-20.89 | <0.001 |
| | | Yes | 718173 | 260 | 3.62 | 3.18-4.06 | | 526 | 7.32 | 6.70-7.95 | | 1134 | 15.79 | 14.87-16.71 | | 3460 | 48.18 | 46.58-49.78 | |
| | Female | No | 146448 | 24 | 1.64 | 0.98-2.29 | <0.001 | 54 | 3.69 | 2.70-4.67 | <0.001 | 118 | 8.06 | 6.60-9.51 | <0.001 | 340 | 23.22 | 20.75-25.68 | <0.001 |
| | | Yes | 740384 | 290 | 3.92 | 3.47-4.37 | | 586 | 7.91 | 7.27-8.56 | | 1307 | 17.65 | 16.70-18.61 | | 4092 | 55.27 | 53.58-56.96 | |
| Periodontal disease | Male | No | 143128 | 0 | 0 | 0.00-0.00 | 0.037 | 0 | 0 | 0.00-0.00 | 0.003 | 5 | 0.35 | 0.04-0.66 | 0.01 | 11 | 0.77 | 0.31-1.22 | <0.001 |
| | | Yes | 718173 | 21 | 0.29 | 0.17-0.42 | | 36 | 0.5 | 0.34-0.67 | | 75 | 1.04 | 0.81-1.28 | | 247 | 3.44 | 3.01-3.87 | |
| | Female | No | 146448 | 5 | 0.34 | 0.04-0.64 | 0.067 | 6 | 0.41 | 0.08-0.74 | 1 | 9 | 0.61 | 0.21-1.02 | 0.071 | 20 | 1.37 | 0.77-1.96 | <0.001 |
| | | Yes | 740384 | 9 | 0.12 | 0.04-0.20 | | 34 | 0.46 | 0.30-0.61 | | 85 | 1.15 | 0.90-1.39 | | 241 | 3.26 | 2.84-3.67 | |

Supplement table S2. The cumulative incidence rates of non-fatal immune-related adverse events stratified by vaccine type

| Disease | Vaccination | total | One week | | | | Two weeks | | | | One month | | | | Three months | | | |
|---------------------|-------------------|--------|----------|------|-----------|----------|-----------|-------|------------|----------|-----------|-------|-------------|----------|--------------|-------|-------------|----------|
| | | | event | IR | 95% CI | <i>P</i> | event | IR | 95% CI | <i>P</i> | event | IR | 95% CI | <i>P</i> | event | IR | 95% CI | <i>P</i> |
| Endometriosis | No | 289576 | 4 | 0.14 | 0.00-0.27 | 0.264 | 13 | 0.45 | 0.20-0.69 | 0.213 | 35 | 1.21 | 0.81-1.61 | 0.002 | 99 | 3.42 | 2.75-4.09 | <0.001 |
| | only mRNA vaccine | 849526 | 22 | 0.26 | 0.15-0.37 | | 41 | 0.48 | 0.33-0.63 | | 109 | 1.28 | 1.04-1.52 | | 401 | 4.72 | 4.26-5.18 | |
| | only cDNA vaccine | 510253 | 8 | 0.16 | 0.05-0.27 | | 15 | 0.29 | 0.15-0.44 | | 37 | 0.73 | 0.49-0.96 | | 97 | 1.9 | 1.52-2.28 | |
| | Cross | 98778 | 4 | 0.4 | 0.01-0.80 | | 7 | 0.71 | 0.18-1.23 | | 19 | 1.92 | 1.06-2.79 | | 86 | 8.71 | 6.87-10.55 | |
| Menstrual disorder | No | 289576 | 82 | 2.83 | 2.22-3.44 | <0.001 | 161 | 5.56 | 4.70-6.42 | <0.001 | 346 | 11.95 | 10.69-13.21 | <0.001 | 1025 | 35.4 | 33.23-37.56 | <0.001 |
| | only mRNA vaccine | 849526 | 334 | 3.93 | 3.51-4.35 | | 685 | 8.06 | 7.46-8.67 | | 1533 | 18.05 | 17.14-18.95 | | 4891 | 57.57 | 55.96-59.18 | |
| | only cDNA vaccine | 510253 | 63 | 1.23 | 0.93-1.54 | | 138 | 2.7 | 2.25-3.16 | | 281 | 5.51 | 4.86-6.15 | | 810 | 15.87 | 14.78-16.97 | |
| | Cross | 98778 | 45 | 4.56 | 3.22-5.89 | | 112 | 11.34 | 9.24-13.44 | | 267 | 27.03 | 23.79-30.27 | | 780 | 78.96 | 73.45-84.48 | |
| Bruise | No | 289576 | 4 | 0.14 | 0.00-0.27 | <0.001 | 6 | 0.21 | 0.04-0.37 | <0.001 | 11 | 0.38 | 0.16-0.60 | <0.001 | 48 | 1.66 | 1.19-2.13 | <0.001 |
| | only mRNA vaccine | 849526 | 56 | 0.66 | 0.49-0.83 | | 86 | 1.01 | 0.80-1.23 | | 142 | 1.67 | 1.40-1.95 | | 296 | 3.48 | 3.09-3.88 | |
| | only cDNA vaccine | 510253 | 47 | 0.92 | 0.66-1.18 | | 87 | 1.71 | 1.35-2.06 | | 131 | 2.57 | 2.13-3.01 | | 231 | 4.53 | 3.94-5.11 | |
| | Cross | 98778 | 4 | 0.4 | 0.01-0.80 | | 8 | 0.81 | 0.25-1.37 | | 14 | 1.42 | 0.67-2.16 | | 32 | 3.24 | 2.12-4.36 | |
| Herpes zoster | No | 289576 | 31 | 1.07 | 0.69-1.45 | <0.001 | 66 | 2.28 | 1.73-2.83 | <0.001 | 162 | 5.59 | 4.73-6.46 | <0.001 | 454 | 15.68 | 14.24-17.12 | <0.001 |
| | only mRNA vaccine | 849526 | 237 | 2.79 | 2.43-3.14 | | 535 | 6.3 | 5.76-6.83 | | 1136 | 13.37 | 12.60-14.15 | | 3365 | 39.61 | 38.27-40.95 | |
| | only cDNA vaccine | 510253 | 215 | 4.21 | 3.65-4.78 | | 463 | 9.07 | 8.25-9.90 | | 987 | 19.34 | 18.14-20.55 | | 2760 | 54.09 | 52.08-56.10 | |
| | Cross | 98778 | 20 | 2.02 | 1.14-2.91 | | 57 | 5.77 | 4.27-7.27 | | 147 | 14.88 | 12.48-17.29 | | 450 | 45.56 | 41.36-49.76 | |
| Alopecia | No | 289576 | 6 | 0.21 | 0.04-0.37 | 0.024 | 10 | 0.35 | 0.13-0.56 | 0.001 | 23 | 0.79 | 0.47-1.12 | <0.001 | 80 | 2.76 | 2.16-3.37 | <0.001 |
| | only mRNA vaccine | 849526 | 41 | 0.48 | 0.33-0.63 | | 82 | 0.97 | 0.76-1.17 | | 175 | 2.06 | 1.75-2.37 | | 482 | 5.67 | 5.17-6.18 | |
| | only cDNA vaccine | 510253 | 13 | 0.25 | 0.12-0.39 | | 28 | 0.55 | 0.35-0.75 | | 63 | 1.23 | 0.93-1.54 | | 195 | 3.82 | 3.29-4.36 | |
| | Cross | 98778 | 7 | 0.71 | 0.18-1.23 | | 12 | 1.21 | 0.53-1.90 | | 28 | 2.83 | 1.78-3.88 | | 89 | 9.01 | 7.14-10.88 | |
| Warts | No | 289576 | 20 | 0.69 | 0.39-0.99 | 0.052 | 30 | 1.04 | 0.67-1.41 | <0.001 | 78 | 2.69 | 2.10-3.29 | <0.001 | 197 | 6.8 | 5.85-7.75 | <0.001 |
| | only mRNA vaccine | 849526 | 89 | 1.05 | 0.83-1.27 | | 197 | 2.32 | 2.00-2.64 | | 433 | 5.1 | 4.62-5.58 | | 1157 | 13.62 | 12.84-14.40 | |
| | only cDNA vaccine | 510253 | 34 | 0.67 | 0.44-0.89 | | 79 | 1.55 | 1.21-1.89 | | 173 | 3.39 | 2.89-3.90 | | 504 | 9.88 | 9.02-10.74 | |
| | Cross | 98778 | 12 | 1.21 | 0.53-1.90 | | 27 | 2.73 | 1.70-3.76 | | 52 | 5.26 | 3.83-6.69 | | 150 | 15.19 | 12.76-17.61 | |
| Visual impairment | No | 289576 | 0 | 0 | 0.00-0.00 | 0.421 | 0 | 0 | 0.00-0.00 | 0.08 | 0 | 0 | 0.00-0.00 | 0.012 | 2 | 0.07 | 0.00-0.16 | <0.001 |
| | only mRNA vaccine | 849526 | 2 | 0.02 | 0.00-0.06 | | 3 | 0.04 | 0.00-0.08 | | 8 | 0.09 | 0.03-0.16 | | 18 | 0.21 | 0.11-0.31 | |
| | only cDNA vaccine | 510253 | 3 | 0.06 | 0.00-0.13 | | 6 | 0.12 | 0.02-0.21 | | 13 | 0.25 | 0.12-0.39 | | 30 | 0.59 | 0.38-0.80 | |
| | Cross | 98778 | 0 | 0 | 0.00-0.00 | | 0 | 0 | 0.00-0.00 | | 2 | 0.2 | 0.00-0.48 | | 2 | 0.2 | 0.00-0.48 | |
| Glaucoma | No | 289576 | 43 | 1.48 | 1.04-1.93 | <0.001 | 80 | 2.76 | 2.16-3.37 | <0.001 | 199 | 6.87 | 5.92-7.83 | <0.001 | 534 | 18.44 | 16.88-20.00 | <0.001 |
| | only mRNA vaccine | 849526 | 218 | 2.57 | 2.23-2.91 | | 449 | 5.29 | 4.80-5.77 | | 966 | 11.37 | 10.65-12.09 | | 3034 | 35.71 | 34.45-36.98 | |
| | only cDNA vaccine | 510253 | 186 | 3.65 | 3.12-4.17 | | 389 | 7.62 | 6.87-8.38 | | 798 | 15.64 | 14.56-16.72 | | 2367 | 46.39 | 44.52-48.25 | |
| | Cross | 98778 | 26 | 2.63 | 1.62-3.64 | | 63 | 6.38 | 4.80-7.95 | | 128 | 12.96 | 10.71-15.20 | | 348 | 35.23 | 31.54-38.93 | |
| Tinnitus | No | 289576 | 11 | 0.38 | 0.16-0.60 | 0.019 | 26 | 0.9 | 0.55-1.24 | 0.002 | 54 | 1.86 | 1.37-2.36 | <0.001 | 171 | 5.91 | 5.02-6.79 | <0.001 |
| | only mRNA vaccine | 849526 | 72 | 0.85 | 0.65-1.04 | | 138 | 1.62 | 1.35-1.90 | | 316 | 3.72 | 3.31-4.13 | | 991 | 11.67 | 10.94-12.39 | |
| | only cDNA vaccine | 510253 | 44 | 0.86 | 0.61-1.12 | | 92 | 1.8 | 1.43-2.17 | | 195 | 3.82 | 3.29-4.36 | | 708 | 13.88 | 12.85-14.90 | |
| | Cross | 98778 | 3 | 0.3 | 0.00-0.65 | | 7 | 0.71 | 0.18-1.23 | | 23 | 2.33 | 1.38-3.28 | | 90 | 9.11 | 7.23-10.99 | |
| Inner ear disease | No | 289576 | 43 | 1.48 | 1.04-1.93 | <0.001 | 71 | 2.45 | 1.88-3.02 | <0.001 | 152 | 5.25 | 4.41-6.08 | <0.001 | 466 | 16.09 | 14.63-17.55 | <0.001 |
| | only mRNA vaccine | 849526 | 297 | 3.5 | 3.10-3.89 | | 582 | 6.85 | 6.29-7.41 | | 1285 | 15.13 | 14.30-15.95 | | 3735 | 43.97 | 42.56-45.37 | |
| | only cDNA vaccine | 510253 | 222 | 4.35 | 3.78-4.92 | | 456 | 8.94 | 8.12-9.76 | | 977 | 19.15 | 17.95-20.35 | | 2793 | 54.74 | 52.71-56.76 | |
| | Cross | 98778 | 34 | 3.44 | 2.29-4.60 | | 56 | 5.67 | 4.18-7.15 | | 119 | 12.05 | 9.88-14.21 | | 342 | 34.62 | 30.96-38.29 | |
| Middle ear disease | No | 289576 | 14 | 0.48 | 0.23-0.74 | <0.001 | 42 | 1.45 | 1.01-1.89 | <0.001 | 93 | 3.21 | 2.56-3.86 | <0.001 | 290 | 10.01 | 8.86-11.17 | <0.001 |
| | only mRNA vaccine | 849526 | 125 | 1.47 | 1.21-1.73 | | 284 | 3.34 | 2.95-3.73 | | 623 | 7.33 | 6.76-7.91 | | 1973 | 23.22 | 22.20-24.25 | |
| | only cDNA vaccine | 510253 | 82 | 1.61 | 1.26-1.95 | | 158 | 3.1 | 2.61-3.58 | | 372 | 7.29 | 6.55-8.03 | | 1157 | 22.68 | 21.37-23.98 | |
| | Cross | 98778 | 11 | 1.11 | 0.46-1.77 | | 26 | 2.63 | 1.62-3.64 | | 63 | 6.38 | 4.80-7.95 | | 213 | 21.56 | 18.67-24.46 | |
| Other ear disease | No | 289576 | 43 | 1.48 | 1.04-1.93 | <0.001 | 86 | 2.97 | 2.34-3.60 | <0.001 | 202 | 6.98 | 6.01-7.94 | <0.001 | 607 | 20.96 | 19.30-22.63 | <0.001 |
| | only mRNA vaccine | 849526 | 323 | 3.8 | 3.39-4.22 | | 655 | 7.71 | 7.12-8.30 | | 1448 | 17.04 | 16.17-17.92 | | 4309 | 50.72 | 49.21-52.23 | |
| | only cDNA vaccine | 510253 | 200 | 3.92 | 3.38-4.46 | | 408 | 8 | 7.22-8.77 | | 886 | 17.36 | 16.22-18.51 | | 2881 | 56.46 | 54.41-58.52 | |
| | Cross | 98778 | 27 | 2.73 | 1.70-3.76 | | 49 | 4.96 | 3.57-6.35 | | 107 | 10.83 | 8.78-12.88 | | 362 | 36.65 | 32.88-40.42 | |
| Periodontal disease | No | 289576 | 5 | 0.17 | 0.02-0.32 | 0.081 | 6 | 0.21 | 0.04-0.37 | <0.001 | 14 | 0.48 | 0.23-0.74 | <0.001 | 31 | 1.07 | 0.69-1.45 | <0.001 |
| | only mRNA vaccine | 849526 | 11 | 0.13 | 0.05-0.21 | | 26 | 0.31 | 0.19-0.42 | | 65 | 0.77 | 0.58-0.95 | | 226 | 2.66 | 2.31-3.01 | |
| | only cDNA vaccine | 510253 | 17 | 0.33 | 0.17-0.49 | | 37 | 0.73 | 0.49-0.96 | | 82 | 1.61 | 1.26-1.95 | | 228 | 4.47 | 3.89-5.05 | |
| | Cross | 98778 | 2 | 0.2 | 0.00-0.48 | | 7 | 0.71 | 0.18-1.23 | | 13 | 1.32 | 0.60-2.03 | | 34 | 3.44 | 2.29-4.60 | |

Supplement table S3. The Cox proportional hazards model of non-fatal immune-related adverse events following COVID-19 vaccination

| Disease | Variables | Value | HR | 95% CI | P | |
|--------------------|-----------------|--------|-------|-------------|-------------|--------|
| Endometriosis | Vaccine | Yes | 1.629 | 1.312-2.022 | <0.001 | |
| | Gender | Female | | | | |
| | Age | | | 0.971 | 0.966-0.976 | <0.001 |
| | Insurance Level | Low | | | | |
| | | Middle | | 0.988 | 0.801-1.220 | 0.913 |
| | | High | | 1.263 | 1.045-1.527 | 0.016 |
| | CCI | 0 | | | | |
| | | 1 | | 0.897 | 0.666-1.209 | 0.477 |
| | | 2≤ | | 1.062 | 0.747-1.511 | 0.736 |
| | DM | | | 0.693 | 0.444-1.080 | 0.105 |
| | HTN | | | 0.599 | 0.436-0.824 | 0.002 |
| | HLD | | | 0.973 | 0.744-1.271 | 0.838 |
| | COPD | | | 0.894 | 0.500-1.602 | 0.707 |
| COVID19 | | | 1.426 | 0.677-3.003 | 0.351 | |
| Menstrual disorder | Vaccine | Yes | 2.022 | 1.892-2.162 | <0.001 | |
| | Gender | Female | | | | |
| | Age | | | 0.945 | 0.943-0.946 | <0.001 |
| | Insurance Level | Low | | | | |
| | | Middle | | 1.077 | 1.014-1.144 | 0.016 |
| | | High | | 1.048 | 0.989-1.110 | 0.115 |
| | CCI | 0 | | | | |
| | | 1 | | 1.337 | 1.227-1.457 | <0.001 |
| | | 2≤ | | 1.299 | 1.157-1.460 | <0.001 |
| | DM | | | 0.825 | 0.713-0.953 | 0.009 |
| | HTN | | | 0.694 | 0.620-0.778 | <0.001 |
| | HLD | | | 0.852 | 0.774-0.937 | 0.001 |
| | COPD | | | 1.024 | 0.872-1.203 | 0.774 |
| COVID19 | | | 1.305 | 1.036-1.643 | 0.024 | |
| Bruise | Vaccine | Yes | 1.805 | 1.337-2.436 | <0.001 | |
| | Gender | Female | 1.527 | 1.295-1.800 | <0.001 | |
| | Age | | | 1.011 | 1.005-1.017 | <0.001 |
| | Insurance Level | Low | | | | |
| | | Middle | | 0.927 | 0.740-1.163 | 0.513 |
| | | High | | 1.089 | 0.898-1.321 | 0.387 |
| | CCI | 0 | | | | |
| | | 1 | | 1.25 | 0.974-1.603 | 0.079 |
| | | 2≤ | | 2.094 | 1.626-2.697 | <0.001 |
| | DM | | | 0.765 | 0.597-0.980 | 0.034 |
| | HTN | | | 1.08 | 0.878-1.328 | 0.466 |
| | HLD | | | 1.203 | 0.975-1.485 | 0.085 |
| | COPD | | | 0.797 | 0.538-1.182 | 0.259 |
| COVID19 | | | 1.032 | 0.428-2.489 | 0.944 | |
| Herpes zoster | Vaccine | Yes | 2.337 | 2.122-2.573 | <0.001 | |
| | Gender | Female | 1.417 | 1.350-1.486 | <0.001 | |
| | Age | | | 1.018 | 1.016-1.019 | <0.001 |
| | Insurance Level | Low | | | | |
| | | Middle | | 1.025 | 0.960-1.094 | 0.455 |
| | | High | | 1.047 | 0.989-1.109 | 0.115 |
| | CCI | 0 | | | | |
| 1 | | | 1.06 | 0.985-1.140 | 0.119 | |

| | | | | | | |
|-------------------|-----------------|---------|---------|--------------|-------------|--------|
| | | 2≤ | 1.101 | 1.013-1.196 | 0.024 | |
| | | DM | 0.899 | 0.831-0.973 | 0.008 | |
| | | HTN | 0.898 | 0.845-0.955 | 0.001 | |
| | | HLD | 1.242 | 1.168-1.321 | <0.001 | |
| | | COPD | 1.09 | 0.971-1.224 | 0.142 | |
| | | COVID19 | 1.236 | 0.969-1.575 | 0.087 | |
| Alopecia | Vaccine | Yes | 2.397 | 1.896-3.029 | <0.001 | |
| | Gender | Female | 1.013 | 0.884-1.160 | 0.854 | |
| | | Age | 0.977 | 0.972-0.982 | <0.001 | |
| | Insurance Level | | Low | | | |
| | | | Middle | 0.849 | 0.705-1.023 | 0.086 |
| | | | High | 0.958 | 0.813-1.130 | 0.613 |
| | CCI | | 0 | | | |
| | | | 1 | 1.248 | 0.993-1.569 | 0.058 |
| | | | 2≤ | 0.862 | 0.631-1.177 | 0.35 |
| | | | DM | 0.763 | 0.564-1.031 | 0.078 |
| | | | HTN | 0.704 | 0.563-0.879 | 0.002 |
| | | | HLD | 1.302 | 1.056-1.606 | 0.014 |
| | | | COPD | 0.992 | 0.638-1.541 | 0.97 |
| | | | COVID19 | 0.937 | 0.420-2.092 | 0.874 |
| Warts | Vaccine | Yes | 2.279 | 1.963-2.647 | <0.001 | |
| | Gender | Female | 0.843 | 0.772-0.921 | <0.001 | |
| | | Age | 0.968 | 0.965-0.971 | <0.001 | |
| | Insurance Level | | Low | | | |
| | | | Middle | 1.021 | 0.901-1.158 | 0.744 |
| | | | High | 1.217 | 1.089-1.362 | 0.001 |
| | CCI | | 0 | | | |
| | | | 1 | 1.27 | 1.095-1.473 | 0.002 |
| | | | 2≤ | 1.231 | 1.023-1.482 | 0.028 |
| | | | DM | 0.704 | 0.584-0.847 | <0.001 |
| | | | HTN | 1.039 | 0.904-1.193 | 0.594 |
| | | | HLD | 1.352 | 1.180-1.550 | <0.001 |
| | | | COPD | 1.069 | 0.820-1.394 | 0.62 |
| | | | COVID19 | 1.087 | 0.674-1.752 | 0.733 |
| Visual impairment | Vaccine | Yes | 3.935 | 0.943-16.410 | 0.06 | |
| | Gender | Female | 0.639 | 0.366-1.117 | 0.116 | |
| | | Age | 1.016 | 0.995-1.037 | 0.133 | |
| | Insurance Level | | Low | | | |
| | | | Middle | 0.913 | 0.439-1.896 | 0.807 |
| | | | High | 0.811 | 0.422-1.556 | 0.528 |
| | CCI | | 0 | | | |
| | | | 1 | 0.792 | 0.323-1.942 | 0.61 |
| | | | 2≤ | 1.325 | 0.532-3.300 | 0.546 |
| | | | DM | 0.735 | 0.300-1.802 | 0.501 |
| | | | HTN | 1.112 | 0.555-2.230 | 0.765 |
| | | | HLD | 1.399 | 0.686-2.854 | 0.355 |
| | | | COPD | 1.185 | 0.343-4.094 | 0.789 |
| | | | COVID19 | | | |
| | Vaccine | Yes | 1.715 | 1.567-1.878 | <0.001 | |
| | Gender | Female | 1.224 | 1.164-1.287 | <0.001 | |
| | | Age | 1.013 | 1.011-1.015 | <0.001 | |
| | Insurance Level | | Low | | | |
| | | | Middle | 0.927 | 0.862-0.997 | 0.041 |

| | | | | | |
|--------------------|-----------------|--------|-------------|-------------|--------|
| Glaucoma | | High | 1.244 | 1.170-1.322 | <0.001 |
| | CCI | 0 | | | |
| | | 1 | 1.132 | 1.048-1.222 | 0.002 |
| | | 2≤ | 1.172 | 1.073-1.279 | <0.001 |
| | DM | | 0.923 | 0.850-1.003 | 0.058 |
| | HTN | | 0.979 | 0.917-1.045 | 0.518 |
| | HLD | | 1.258 | 1.177-1.344 | <0.001 |
| | COPD | | 1.059 | 0.937-1.197 | 0.358 |
| | COVID19 | | 1.234 | 0.957-1.591 | 0.106 |
| Tinnitus | Vaccine | Yes | 1.778 | 1.515-2.087 | <0.001 |
| | Gender | Female | 1.218 | 1.114-1.333 | <0.001 |
| | Age | | 1.009 | 1.005-1.012 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 1.039 | 0.920-1.174 | 0.535 |
| | | High | 1.011 | 0.906-1.127 | 0.85 |
| | CCI | 0 | | | |
| | | 1 | 1.139 | 0.992-1.309 | 0.066 |
| | | 2≤ | 1.174 | 1.000-1.377 | 0.049 |
| | DM | | 0.886 | 0.762-1.031 | 0.118 |
| | HTN | | 0.921 | 0.818-1.038 | 0.177 |
| | HLD | | 1.315 | 1.167-1.483 | <0.001 |
| | COPD | | 1.045 | 0.834-1.310 | 0.703 |
| COVID19 | | 1.119 | 0.694-1.804 | 0.646 | |
| Inner ear disease | Vaccine | Yes | 2.368 | 2.153-2.604 | <0.001 |
| | Gender | Female | 1.998 | 1.902-2.099 | <0.001 |
| | Age | | 1.015 | 1.013-1.017 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 1.033 | 0.970-1.101 | 0.312 |
| | | High | 1.051 | 0.994-1.112 | 0.082 |
| | CCI | 0 | | | |
| | | 1 | 1.151 | 1.074-1.234 | <0.001 |
| | | 2≤ | 1.174 | 1.084-1.272 | <0.001 |
| | DM | | 0.771 | 0.713-0.832 | <0.001 |
| | HTN | | 0.974 | 0.918-1.035 | 0.398 |
| | HLD | | 1.295 | 1.220-1.375 | <0.001 |
| | COPD | | 1.253 | 1.127-1.392 | <0.001 |
| COVID19 | | 1.283 | 1.017-1.618 | 0.036 | |
| Middle ear disease | Vaccine | Yes | 2.212 | 1.958-2.500 | <0.001 |
| | Gender | Female | 1.208 | 1.131-1.290 | <0.001 |
| | Age | | 0.996 | 0.994-0.998 | 0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 1.039 | 0.950-1.136 | 0.404 |
| | | High | 1.023 | 0.944-1.109 | 0.581 |
| | CCI | 0 | | | |
| | | 1 | 1.25 | 1.127-1.386 | <0.001 |
| | | 2≤ | 1.488 | 1.323-1.674 | <0.001 |
| | DM | | 0.875 | 0.781-0.982 | 0.023 |
| | HTN | | 0.981 | 0.896-1.075 | 0.686 |
| | HLD | | 1.112 | 1.015-1.219 | 0.023 |
| | COPD | | 1.237 | 1.057-1.447 | 0.008 |
| COVID19 | | 1.219 | 0.874-1.701 | 0.243 | |
| Vaccine | Yes | 1.9 | 1.746-2.066 | <0.001 | |
| Gender | Female | 1.132 | 1.084-1.183 | <0.001 | |

| | | | | | |
|---------------------|-----------------|--------|-------------|-------------|--------|
| Other ear disease | Age | | 1.02 | 1.019-1.022 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 0.972 | 0.914-1.032 | 0.353 |
| | | High | 1.029 | 0.976-1.085 | 0.291 |
| | CCI | 0 | | | |
| | | 1 | 1.121 | 1.049-1.198 | 0.001 |
| | | 2≤ | 1.199 | 1.112-1.294 | <0.001 |
| | DM | | 0.917 | 0.855-0.984 | 0.016 |
| | HTN | | 0.994 | 0.940-1.051 | 0.836 |
| | HLD | | 1.192 | 1.126-1.262 | <0.001 |
| | COPD | | 1.26 | 1.144-1.389 | <0.001 |
| | COVID19 | | 1.218 | 0.975-1.523 | 0.083 |
| Periodontal disease | Vaccine | Yes | 2.084 | 1.443-3.009 | <0.001 |
| | Gender | Female | 0.958 | 0.806-1.140 | 0.63 |
| | Age | | 1.032 | 1.025-1.039 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 0.81 | 0.642-1.022 | 0.076 |
| | | High | 0.767 | 0.627-0.937 | 0.009 |
| | CCI | 0 | | | |
| | | 1 | 1.372 | 1.058-1.779 | 0.017 |
| | | 2≤ | 1.51 | 1.130-2.016 | 0.005 |
| | DM | | 1.218 | 0.950-1.562 | 0.12 |
| | HTN | | 1.06 | 0.857-1.311 | 0.589 |
| | HLD | | 1.089 | 0.874-1.358 | 0.447 |
| COPD | | 1.339 | 0.961-1.867 | 0.084 | |
| COVID19 | | 1.861 | 0.925-3.746 | 0.082 | |

Supplement table S4. Multivariate logistic regression model of non-fatal immune-related adverse events following COVID-19 vaccination

| Disease | Variable | Value | One week | | | Two weeks | | | One month | | | Three months | | | |
|--------------------|-----------------|--------|-------------|--------------|-------------|--------------|--------------|-------------|-------------|-------------|-------------|--------------|-------------|-------------|--------|
| | | | OR | 95% CI | <i>P</i> | OR | 95% CI | <i>P</i> | OR | 95% CI | <i>P</i> | OR | 95% CI | <i>P</i> | |
| Endometriosis | Vaccine | Yes | 2.381 | 0.835-6.795 | 0.105 | 1.344 | 0.732-2.467 | 0.341 | 1.261 | 0.869-1.830 | 0.222 | 1.631 | 1.313-2.025 | <0.001 | |
| | Gender | Female | | | | | | | | | | | | | |
| | Age | | 0.976 | 0.954-0.998 | 0.034 | 0.979 | 0.963-0.995 | 0.009 | 0.973 | 0.964-0.983 | <0.001 | 0.971 | 0.966-0.976 | <0.001 | |
| | Insurance Level | Low | | | | | | | | | | | | | |
| | | Middle | | 0.803 | 0.334-1.935 | 0.626 | 1.091 | 0.546-2.179 | 0.806 | 1.151 | 0.771-1.719 | 0.492 | 0.988 | 0.801-1.220 | 0.914 |
| | | High | | 1.066 | 0.492-2.310 | 0.871 | 1.842 | 1.007-3.368 | 0.047 | 1.497 | 1.041-2.152 | 0.03 | 1.263 | 1.045-1.527 | 0.016 |
| | CCI | 0 | | | | | | | | | | | | | |
| | | 1 | | 0.422 | 0.083-2.153 | 0.3 | 0.535 | 0.176-1.625 | 0.27 | 0.815 | 0.465-1.429 | 0.475 | 0.897 | 0.666-1.209 | 0.476 |
| | | 2≤ | | 0.292 | 0.030-2.801 | 0.286 | 0.285 | 0.056-1.454 | 0.131 | 0.696 | 0.339-1.430 | 0.324 | 1.061 | 0.746-1.508 | 0.743 |
| | DM | | 0.766 | 0.066-8.920 | 0.831 | 1.449 | 0.307-6.846 | 0.639 | 0.974 | 0.446-2.128 | 0.948 | 0.693 | 0.444-1.080 | 0.105 | |
| | HTN | | 0.561 | 0.144-2.188 | 0.406 | 0.358 | 0.116-1.104 | 0.074 | 0.692 | 0.397-1.208 | 0.196 | 0.599 | 0.436-0.823 | 0.002 | |
| | HLD | | 1.335 | 0.460-3.872 | 0.595 | 1.047 | 0.462-2.374 | 0.912 | 1.059 | 0.652-1.720 | 0.816 | 0.973 | 0.745-1.271 | 0.842 | |
| | COPD | | 0 | 0.000-.00 | 0.979 | 0 | 0.000-.00 | 0.98 | 0.792 | 0.238-2.633 | 0.703 | 0.894 | 0.499-1.601 | 0.706 | |
| COVID19 | | 0 | 0.000-.00 | 0.988 | 1.955 | 0.272-14.067 | 0.506 | 1.401 | 0.348-5.644 | 0.636 | 1.425 | 0.676-3.003 | 0.352 | | |
| Menstrual disorder | Vaccine | Yes | 1.68 | 1.323-2.134 | <0.001 | 1.821 | 1.537-2.157 | <0.001 | 1.901 | 1.694-2.133 | <0.001 | 2.037 | 1.905-2.178 | <0.001 | |
| | Gender | Female | | | | | | | | | | | | | |
| | Age | | 0.944 | 0.937-0.950 | <0.001 | 0.945 | 0.940-0.949 | <0.001 | 0.946 | 0.943-0.949 | <0.001 | 0.944 | 0.943-0.946 | <0.001 | |
| | Insurance Level | Low | | | | | | | | | | | | | |
| | | Middle | | 1.015 | 0.813-1.267 | 0.898 | 1.018 | 0.869-1.192 | 0.824 | 1.077 | 0.969-1.197 | 0.168 | 1.077 | 1.014-1.145 | 0.016 |
| | | High | | 0.914 | 0.736-1.136 | 0.419 | 1.039 | 0.894-1.208 | 0.616 | 1.029 | 0.929-1.139 | 0.586 | 1.049 | 0.990-1.112 | 0.108 |
| | CCI | 0 | | | | | | | | | | | | | |
| | | 1 | | 1.557 | 1.143-2.120 | 0.005 | 1.365 | 1.094-1.704 | 0.006 | 1.331 | 1.145-1.547 | <0.001 | 1.342 | 1.230-1.463 | <0.001 |
| | | 2≤ | | 1.416 | 0.929-2.158 | 0.106 | 1.342 | 0.999-1.803 | 0.051 | 1.217 | 0.991-1.496 | 0.061 | 1.301 | 1.158-1.463 | <0.001 |
| | DM | | 1.063 | 0.658-1.716 | 0.803 | 0.841 | 0.589-1.203 | 0.343 | 0.884 | 0.692-1.130 | 0.324 | 0.823 | 0.712-0.952 | 0.009 | |
| | HTN | | 0.644 | 0.426-0.974 | 0.037 | 0.647 | 0.484-0.866 | 0.003 | 0.726 | 0.599-0.881 | 0.001 | 0.696 | 0.621-0.780 | <0.001 | |
| | HLD | | 0.997 | 0.706-1.407 | 0.985 | 1.028 | 0.811-1.303 | 0.822 | 0.904 | 0.767-1.066 | 0.231 | 0.852 | 0.774-0.938 | 0.001 | |
| | COPD | | 0.948 | 0.525-1.714 | 0.86 | 0.946 | 0.617-1.449 | 0.799 | 1.031 | 0.777-1.368 | 0.833 | 1.025 | 0.871-1.206 | 0.767 | |
| COVID19 | | 1.25 | 0.517-3.018 | 0.62 | 1.708 | 1.007-2.897 | 0.047 | 1.491 | 1.019-2.183 | 0.04 | 1.309 | 1.036-1.652 | 0.024 | | |
| Bruise | Vaccine | Yes | 4.521 | 1.649-12.397 | 0.003 | 4.687 | 2.064-10.643 | <0.001 | 4.091 | 2.228-7.513 | <0.001 | 1.814 | 1.344-2.449 | <0.001 | |
| | Gender | Female | 1.515 | 1.030-2.228 | 0.035 | 1.734 | 1.282-2.344 | <0.001 | 1.624 | 1.282-2.058 | <0.001 | 1.527 | 1.296-1.800 | <0.001 | |
| | Age | | 0.995 | 0.981-1.009 | 0.455 | 0.999 | 0.988-1.010 | 0.887 | 1.004 | 0.995-1.012 | 0.42 | 1.011 | 1.005-1.017 | <0.001 | |
| | Insurance Level | Low | | | | | | | | | | | | | |
| | | Middle | | 0.822 | 0.490-1.380 | 0.459 | 0.788 | 0.524-1.185 | 0.253 | 0.971 | 0.705-1.337 | 0.855 | 0.927 | 0.740-1.163 | 0.513 |
| | | High | | 0.935 | 0.600-1.458 | 0.767 | 0.994 | 0.708-1.397 | 0.973 | 1.076 | 0.815-1.420 | 0.606 | 1.089 | 0.898-1.321 | 0.386 |
| | CCI | 0 | | | | | | | | | | | | | |
| | | 1 | | 1.118 | 0.629-1.988 | 0.704 | 1.467 | 0.957-2.247 | 0.078 | 1.556 | 1.107-2.187 | 0.011 | 1.25 | 0.974-1.603 | 0.079 |
| | | 2≤ | | 1.176 | 0.612-2.259 | 0.627 | 1.935 | 1.226-3.055 | 0.005 | 2.319 | 1.623-3.313 | <0.001 | 2.091 | 1.623-2.693 | <0.001 |
| | DM | | 0.826 | 0.449-1.517 | 0.537 | 0.683 | 0.442-1.056 | 0.086 | 0.71 | 0.504-1.001 | 0.051 | 0.765 | 0.597-0.980 | 0.034 | |
| | HTN | | 0.834 | 0.513-1.356 | 0.465 | 1.025 | 0.710-1.479 | 0.895 | 0.955 | 0.714-1.279 | 0.759 | 1.08 | 0.878-1.328 | 0.467 | |
| | HLD | | 2.496 | 1.523-4.091 | <0.001 | 1.976 | 1.355-2.882 | <0.001 | 1.558 | 1.156-2.099 | 0.004 | 1.204 | 0.976-1.486 | 0.083 | |
| | COPD | | 0.824 | 0.291-2.329 | 0.715 | 0.558 | 0.242-1.286 | 0.171 | 0.668 | 0.368-1.211 | 0.183 | 0.796 | 0.537-1.180 | 0.256 | |
| COVID19 | | 1.179 | 0.164-8.453 | 0.87 | 1.39 | 0.345-5.602 | 0.644 | 1.286 | 0.412-4.013 | 0.665 | 1.03 | 0.427-2.485 | 0.948 | | |
| Vaccine | Yes | 2.558 | 1.770-3.698 | <0.001 | 2.635 | 2.048-3.391 | <0.001 | 2.281 | 1.940-2.681 | <0.001 | 2.354 | 2.137-2.592 | <0.001 | | |
| Gender | Female | 1.489 | 1.243-1.783 | <0.001 | 1.51 | 1.338-1.705 | <0.001 | 1.443 | 1.330-1.566 | <0.001 | 1.418 | 1.352-1.488 | <0.001 | | |

| | | | | | | | | | | | | | | |
|--------------------|-----------------|---------|-------------|--------------|-------------|-------------|--------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| visual impairments | CCI | 1 | 1.36 | 0.070-26.532 | 0.839 | 1.73 | 0.224-13.341 | 0.599 | 0.729 | 0.181-2.933 | 0.656 | 0.791 | 0.323-1.941 | 0.609 |
| | | 2≤ | 3.018 | 0.182-50.059 | 0.441 | 1.497 | 0.152-14.756 | 0.73 | 2.147 | 0.631-7.314 | 0.222 | 1.323 | 0.531-3.295 | 0.548 |
| | DM | | 0.653 | 0.085-5.032 | 0.682 | 1.068 | 0.216-5.268 | 0.936 | 0.554 | 0.166-1.851 | 0.338 | 0.735 | 0.300-1.802 | 0.501 |
| | HTN | | 2.217 | 0.196-25.122 | 0.52 | 2.337 | 0.396-13.787 | 0.349 | 1.409 | 0.516-3.848 | 0.503 | 1.112 | 0.554-2.230 | 0.765 |
| | HLD | | 2.536 | 0.219-29.324 | 0.456 | 2.313 | 0.382-14.007 | 0.362 | 1.047 | 0.379-2.892 | 0.93 | 1.401 | 0.687-2.856 | 0.354 |
| | COPD | | 1.977 | 0.194-20.169 | 0.565 | 3.213 | 0.568-18.180 | 0.187 | 1.964 | 0.520-7.415 | 0.32 | 1.183 | 0.342-4.088 | 0.791 |
| | COVID19 | | 0 | 0.000-.00 | 0.99 | 0 | 0.000-.00 | 0.991 | 0 | 0.000-.00 | 0.989 | 0 | 0.000-.00 | 0.983 |
| | Glaucoma | Vaccine | Yes | 1.581 | 1.148-2.178 | 0.005 | 1.788 | 1.416-2.256 | <0.001 | 1.501 | 1.292-1.742 | <0.001 | 1.725 | 1.576-1.889 |
| Gender | | Female | 1.217 | 1.013-1.461 | 0.036 | 1.286 | 1.133-1.461 | <0.001 | 1.207 | 1.106-1.316 | <0.001 | 1.225 | 1.164-1.288 | <0.001 |
| Age | | 1.015 | 1.008-1.021 | <0.001 | 1.015 | 1.010-1.019 | <0.001 | 1.014 | 1.011-1.017 | <0.001 | 1.013 | 1.011-1.015 | <0.001 | |
| Insurance Level | | Low | | | | | | | | | | | | |
| | | Middle | 0.994 | 0.755-1.309 | 0.968 | 0.987 | 0.820-1.189 | 0.894 | 0.958 | 0.846-1.085 | 0.503 | 0.927 | 0.862-0.997 | 0.041 |
| | | High | 1.478 | 1.175-1.859 | 0.001 | 1.318 | 1.127-1.541 | 0.001 | 1.203 | 1.083-1.338 | 0.001 | 1.245 | 1.171-1.323 | <0.001 |
| CCI | | 0 | | | | | | | | | | | | |
| | | 1 | 1.11 | 0.841-1.466 | 0.461 | 1.114 | 0.918-1.353 | 0.274 | 1.114 | 0.975-1.274 | 0.113 | 1.132 | 1.048-1.223 | 0.002 |
| | | 2≤ | 1.026 | 0.741-1.420 | 0.879 | 1.044 | 0.832-1.310 | 0.708 | 1.076 | 0.922-1.257 | 0.352 | 1.17 | 1.071-1.277 | 0.001 |
| DM | | 0.803 | 0.589-1.093 | 0.163 | 0.957 | 0.775-1.181 | 0.68 | 0.975 | 0.845-1.124 | 0.723 | 0.923 | 0.850-1.003 | 0.059 | |
| HTN | | 0.997 | 0.786-1.265 | 0.981 | 0.996 | 0.845-1.174 | 0.963 | 0.928 | 0.829-1.039 | 0.194 | 0.978 | 0.917-1.044 | 0.513 | |
| HLD | | 1.323 | 1.042-1.681 | 0.022 | 1.225 | 1.037-1.448 | 0.017 | 1.348 | 1.202-1.512 | <0.001 | 1.26 | 1.179-1.346 | <0.001 | |
| COPD | | 1.026 | 0.646-1.629 | 0.915 | 1.099 | 0.805-1.498 | 0.553 | 1.133 | 0.919-1.397 | 0.241 | 1.057 | 0.935-1.196 | 0.376 | |
| COVID19 | | 2.237 | 1.111-4.504 | 0.024 | 1.463 | 0.807-2.652 | 0.21 | 1.039 | 0.644-1.676 | 0.875 | 1.232 | 0.955-1.590 | 0.109 | |
| Tinnitus | Vaccine | Yes | 1.84 | 0.981-3.451 | 0.058 | 1.513 | 1.000-2.287 | 0.05 | 1.688 | 1.269-2.247 | <0.001 | 1.787 | 1.523-2.098 | <0.001 |
| | Gender | Female | 1.376 | 0.968-1.957 | 0.075 | 1.191 | 0.932-1.521 | 0.162 | 1.18 | 1.002-1.389 | 0.048 | 1.219 | 1.114-1.333 | <0.001 |
| | Age | | 1.013 | 1.001-1.026 | 0.039 | 1.014 | 1.005-1.023 | 0.002 | 1.011 | 1.005-1.017 | <0.001 | 1.009 | 1.005-1.012 | <0.001 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 1.175 | 0.740-1.866 | 0.495 | 1.137 | 0.821-1.574 | 0.44 | 1.107 | 0.888-1.379 | 0.367 | 1.039 | 0.920-1.174 | 0.535 |
| | | High | 0.958 | 0.624-1.473 | 0.846 | 0.952 | 0.705-1.285 | 0.748 | 0.982 | 0.803-1.200 | 0.856 | 1.011 | 0.906-1.127 | 0.848 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 1.095 | 0.640-1.874 | 0.741 | 1.218 | 0.840-1.767 | 0.297 | 1.096 | 0.849-1.415 | 0.482 | 1.139 | 0.991-1.309 | 0.066 |
| | | 2≤ | 1.19 | 0.647-2.190 | 0.576 | 1.318 | 0.863-2.013 | 0.202 | 1.308 | 0.985-1.738 | 0.064 | 1.171 | 0.998-1.374 | 0.053 |
| | DM | | 0.77 | 0.422-1.404 | 0.393 | 0.794 | 0.528-1.196 | 0.27 | 0.793 | 0.600-1.048 | 0.102 | 0.886 | 0.762-1.032 | 0.119 |
| | HTN | | 0.991 | 0.626-1.569 | 0.971 | 1.064 | 0.772-1.465 | 0.705 | 1.014 | 0.817-1.259 | 0.901 | 0.921 | 0.818-1.037 | 0.175 |
| | HLD | | 1.19 | 0.750-1.888 | 0.461 | 1.071 | 0.774-1.483 | 0.679 | 1.171 | 0.941-1.458 | 0.157 | 1.317 | 1.168-1.485 | <0.001 |
| COPD | | 0.871 | 0.341-2.224 | 0.773 | 1.138 | 0.643-2.016 | 0.657 | 0.981 | 0.648-1.485 | 0.929 | 1.043 | 0.832-1.307 | 0.715 | |
| COVID19 | | 1.009 | 0.141-7.223 | 0.993 | 1.447 | 0.463-4.520 | 0.525 | 1.092 | 0.452-2.635 | 0.845 | 1.116 | 0.692-1.801 | 0.652 | |
| Inner ear disease | Vaccine | Yes | 2.216 | 1.617-3.037 | <0.001 | 2.557 | 2.005-3.261 | <0.001 | 2.563 | 2.170-3.026 | <0.001 | 2.386 | 2.169-2.624 | <0.001 |
| | Gender | Female | 2.137 | 1.794-2.545 | <0.001 | 2.014 | 1.779-2.279 | <0.001 | 1.906 | 1.754-2.072 | <0.001 | 2.002 | 1.906-2.104 | <0.001 |
| | Age | | 1.01 | 1.004-1.016 | 0.001 | 1.013 | 1.009-1.017 | <0.001 | 1.014 | 1.011-1.017 | <0.001 | 1.015 | 1.013-1.017 | <0.001 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 1.139 | 0.916-1.415 | 0.242 | 1.109 | 0.945-1.302 | 0.205 | 1.042 | 0.934-1.162 | 0.462 | 1.033 | 0.970-1.101 | 0.312 |
| | | High | 0.985 | 0.807-1.203 | 0.881 | 1.107 | 0.959-1.277 | 0.164 | 1.101 | 1.000-1.212 | 0.05 | 1.051 | 0.994-1.112 | 0.082 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 1.05 | 0.819-1.346 | 0.7 | 1.074 | 0.901-1.281 | 0.427 | 1.091 | 0.968-1.230 | 0.152 | 1.152 | 1.074-1.235 | <0.001 |
| | | 2≤ | 0.934 | 0.692-1.260 | 0.656 | 0.99 | 0.803-1.220 | 0.924 | 1.054 | 0.916-1.212 | 0.463 | 1.173 | 1.082-1.271 | <0.001 |
| | DM | | 0.742 | 0.555-0.992 | 0.044 | 0.771 | 0.630-0.942 | 0.011 | 0.835 | 0.731-0.954 | 0.008 | 0.77 | 0.712-0.832 | <0.001 |
| | HTN | | 1.095 | 0.882-1.358 | 0.411 | 1.04 | 0.893-1.211 | 0.614 | 0.96 | 0.866-1.064 | 0.433 | 0.974 | 0.917-1.035 | 0.396 |
| | HLD | | 1.241 | 1.001-1.537 | 0.049 | 1.262 | 1.084-1.469 | 0.003 | 1.303 | 1.175-1.443 | <0.001 | 1.298 | 1.222-1.378 | <0.001 |

| | | | | | | | | | | | | | | | |
|---------------------|-----------------|--------|--------------|-------------|--------|--------------|-------------|--------|-------------|-------------|--------|-------------|-------------|--------|--|
| | COPD | | 1.447 | 0.991-2.113 | 0.056 | 1.364 | 1.043-1.783 | 0.024 | 1.475 | 1.240-1.756 | <0.001 | 1.252 | 1.126-1.392 | <0.001 | |
| | COVID19 | | 0.658 | 0.212-2.048 | 0.47 | 1.36 | 0.770-2.404 | 0.29 | 1.128 | 0.741-1.718 | 0.574 | 1.281 | 1.015-1.618 | 0.037 | |
| Middle ear disease | Vaccine | Yes | 2.726 | 1.575-4.718 | <0.001 | 2.063 | 1.495-2.848 | <0.001 | 2.123 | 1.710-2.635 | <0.001 | 2.222 | 1.966-2.511 | <0.001 | |
| | Gender | Female | 1.147 | 0.884-1.488 | 0.302 | 1.175 | 0.986-1.401 | 0.072 | 1.128 | 1.004-1.268 | 0.043 | 1.208 | 1.131-1.291 | <0.001 | |
| | Age | | 1.002 | 0.993-1.012 | 0.628 | 0.994 | 0.987-1.000 | 0.049 | 0.996 | 0.992-1.000 | 0.082 | 0.996 | 0.994-0.998 | 0.001 | |
| | Insurance Level | Low | | | | | | | | | | | | | |
| | | Middle | 1.135 | 0.795-1.621 | 0.485 | 1.141 | 0.899-1.447 | 0.279 | 1.079 | 0.920-1.265 | 0.35 | 1.039 | 0.950-1.136 | 0.403 | |
| | | High | 1.072 | 0.776-1.480 | 0.675 | 1.044 | 0.839-1.299 | 0.698 | 1.043 | 0.903-1.205 | 0.563 | 1.023 | 0.944-1.109 | 0.579 | |
| | CCI | 0 | | | | | | | | | | | | | |
| | | 1 | 1.338 | 0.901-1.985 | 0.149 | 1.419 | 1.083-1.859 | 0.011 | 1.27 | 1.057-1.525 | 0.011 | 1.25 | 1.127-1.386 | <0.001 | |
| | | 2≤ | 1.255 | 0.785-2.005 | 0.343 | 1.721 | 1.269-2.333 | <0.001 | 1.693 | 1.383-2.071 | <0.001 | 1.486 | 1.321-1.672 | <0.001 | |
| | DM | | 1.014 | 0.661-1.556 | 0.95 | 0.865 | 0.647-1.157 | 0.33 | 0.819 | 0.672-0.998 | 0.048 | 0.875 | 0.781-0.982 | 0.023 | |
| | HTN | | 1.077 | 0.764-1.520 | 0.671 | 1.055 | 0.832-1.338 | 0.659 | 1.057 | 0.902-1.239 | 0.494 | 0.981 | 0.896-1.074 | 0.681 | |
| | HLD | | 1.122 | 0.789-1.596 | 0.521 | 1.215 | 0.953-1.548 | 0.116 | 1.149 | 0.978-1.351 | 0.091 | 1.113 | 1.016-1.221 | 0.022 | |
| COPD | | 1.268 | 0.698-2.302 | 0.435 | 1.114 | 0.734-1.690 | 0.613 | 1.092 | 0.824-1.447 | 0.541 | 1.235 | 1.056-1.445 | 0.008 | | |
| COVID19 | | 2.207 | 0.820-5.939 | 0.117 | 0.973 | 0.364-2.604 | 0.957 | 1.531 | 0.903-2.594 | 0.114 | 1.218 | 0.872-1.700 | 0.247 | | |
| Other ear disease | Vaccine | Yes | 1.907 | 1.392-2.612 | <0.001 | 1.947 | 1.558-2.433 | <0.001 | 1.823 | 1.575-2.109 | <0.001 | 1.915 | 1.761-2.083 | <0.001 | |
| | Gender | Female | 1.054 | 0.896-1.240 | 0.525 | 1.088 | 0.971-1.220 | 0.146 | 1.111 | 1.028-1.200 | 0.008 | 1.133 | 1.085-1.184 | <0.001 | |
| | Age | | 1.026 | 1.020-1.033 | <0.001 | 1.022 | 1.018-1.027 | <0.001 | 1.023 | 1.020-1.026 | <0.001 | 1.02 | 1.019-1.022 | <0.001 | |
| | Insurance Level | Low | | | | | | | | | | | | | |
| | | Middle | 1.045 | 0.835-1.308 | 0.698 | 1.036 | 0.884-1.213 | 0.663 | 1.051 | 0.944-1.170 | 0.36 | 0.972 | 0.914-1.033 | 0.353 | |
| | | High | 1.035 | 0.850-1.261 | 0.73 | 1.045 | 0.910-1.201 | 0.531 | 1.083 | 0.986-1.190 | 0.097 | 1.029 | 0.976-1.085 | 0.289 | |
| | CCI | 0 | | | | | | | | | | | | | |
| | | 1 | 1.308 | 1.029-1.664 | 0.029 | 1.269 | 1.070-1.505 | 0.006 | 1.131 | 1.006-1.271 | 0.04 | 1.121 | 1.048-1.199 | 0.001 | |
| | | 2≤ | 1.649 | 1.269-2.141 | <0.001 | 1.447 | 1.196-1.750 | <0.001 | 1.273 | 1.117-1.451 | <0.001 | 1.197 | 1.109-1.291 | <0.001 | |
| | DM | | 0.679 | 0.526-0.878 | 0.003 | 0.806 | 0.673-0.965 | 0.019 | 0.901 | 0.797-1.019 | 0.096 | 0.917 | 0.855-0.984 | 0.016 | |
| | HTN | | 0.99 | 0.806-1.215 | 0.922 | 1.036 | 0.897-1.198 | 0.629 | 0.995 | 0.902-1.097 | 0.917 | 0.994 | 0.940-1.051 | 0.833 | |
| | HLD | | 1.071 | 0.870-1.319 | 0.518 | 1.102 | 0.950-1.277 | 0.199 | 1.161 | 1.051-1.283 | 0.003 | 1.194 | 1.128-1.265 | <0.001 | |
| COPD | | 1.073 | 0.751-1.531 | 0.699 | 1.13 | 0.878-1.454 | 0.342 | 1.081 | 0.906-1.291 | 0.387 | 1.259 | 1.142-1.388 | <0.001 | | |
| COVID19 | | 0.849 | 0.317-2.271 | 0.744 | 1.16 | 0.640-2.102 | 0.625 | 1.403 | 0.972-2.025 | 0.07 | 1.215 | 0.971-1.520 | 0.088 | | |
| Periodontal disease | Vaccine | Yes | 0.965 | 0.366-2.546 | 0.943 | 1.771 | 0.760-4.126 | 0.186 | 1.662 | 0.955-2.893 | 0.073 | 2.106 | 1.459-3.041 | <0.001 | |
| | Gender | Female | 0.638 | 0.323-1.258 | 0.195 | 1.086 | 0.690-1.709 | 0.721 | 1.136 | 0.841-1.534 | 0.406 | 0.959 | 0.806-1.140 | 0.632 | |
| | Age | | 1.028 | 1.003-1.053 | 0.027 | 1.024 | 1.006-1.041 | 0.007 | 1.025 | 1.013-1.037 | <0.001 | 1.032 | 1.025-1.039 | <0.001 | |
| | Insurance Level | Low | | | | | | | | | | | | | |
| | | Middle | 1.856 | 0.684-5.033 | 0.224 | 1.083 | 0.577-2.034 | 0.804 | 0.729 | 0.488-1.087 | 0.121 | 0.81 | 0.642-1.022 | 0.076 | |
| | | High | 1.676 | 0.664-4.231 | 0.274 | 1.091 | 0.627-1.899 | 0.758 | 0.708 | 0.503-0.998 | 0.049 | 0.767 | 0.627-0.937 | 0.01 | |
| | CCI | 0 | | | | | | | | | | | | | |
| | | 1 | 0.9 | 0.288-2.817 | 0.857 | 1.084 | 0.517-2.275 | 0.831 | 1.326 | 0.830-2.117 | 0.237 | 1.372 | 1.058-1.779 | 0.017 | |
| | | 2≤ | 1.754 | 0.561-5.487 | 0.334 | 2.044 | 0.976-4.280 | 0.058 | 2.17 | 1.340-3.517 | 0.002 | 1.506 | 1.127-2.011 | 0.006 | |
| | DM | | 1.272 | 0.425-3.808 | 0.667 | 1.38 | 0.692-2.753 | 0.361 | 1.25 | 0.809-1.932 | 0.314 | 1.218 | 0.950-1.562 | 0.12 | |
| | HTN | | 0.595 | 0.244-1.452 | 0.254 | 1.034 | 0.582-1.840 | 0.908 | 1.172 | 0.805-1.706 | 0.408 | 1.06 | 0.857-1.311 | 0.59 | |
| | HLD | | 0.833 | 0.331-2.098 | 0.699 | 0.75 | 0.412-1.365 | 0.346 | 0.793 | 0.539-1.168 | 0.241 | 1.091 | 0.875-1.361 | 0.438 | |
| COPD | | 1.686 | 0.464-6.126 | 0.427 | 0.824 | 0.289-2.351 | 0.717 | 1.013 | 0.548-1.872 | 0.968 | 1.337 | 0.959-1.864 | 0.086 | | |
| COVID19 | | 3.385 | 0.461-24.880 | 0.231 | 3.265 | 0.799-13.342 | 0.099 | 2.74 | 1.014-7.403 | 0.047 | 1.856 | 0.922-3.737 | 0.083 | | |

Supplement table S5. The Cox proportional hazards model of non-fatal immune-related adverse events according to vaccine types

| Disease | Variables | Value | HR | 95% CI | P |
|--------------------|-----------------|-------------------|-------------|-------------|--------|
| Endometriosis | Vaccine | No | | | |
| | | only mRNA vaccine | 1.603 | 1.285-2.000 | <0.001 |
| | | only cDNA vaccine | 1.078 | 0.798-1.455 | 0.627 |
| | | Cross | 2.784 | 2.083-3.722 | <0.001 |
| | Gender | Female | | | |
| | Age | | 0.974 | 0.969-0.980 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 1.004 | 0.813-1.240 | 0.968 |
| | | High | 1.291 | 1.068-1.561 | 0.008 |
| | CCI | 0 | | | |
| | | 1 | 0.901 | 0.669-1.214 | 0.495 |
| | | 2≤ | 1.058 | 0.744-1.505 | 0.752 |
| | DM | | 0.698 | 0.447-1.087 | 0.112 |
| | HTN | | 0.617 | 0.448-0.850 | 0.003 |
| | HLD | | 1.019 | 0.780-1.333 | 0.888 |
| COPD | | 0.896 | 0.500-1.604 | 0.712 | |
| COVID19 | | 1.445 | 0.686-3.044 | 0.332 | |
| Menstrual disorder | Vaccine | No | | | |
| | | only mRNA vaccine | 2.019 | 1.887-2.160 | <0.001 |
| | | only cDNA vaccine | 1.454 | 1.317-1.604 | <0.001 |
| | | Cross | 2.837 | 2.582-3.117 | <0.001 |
| | Gender | Female | | | |
| | Age | | 0.947 | 0.945-0.948 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 1.086 | 1.022-1.153 | 0.007 |
| | | High | 1.063 | 1.003-1.127 | 0.039 |
| | CCI | 0 | | | |
| | | 1 | 1.339 | 1.228-1.459 | <0.001 |
| | | 2≤ | 1.298 | 1.156-1.458 | <0.001 |
| | DM | | 0.833 | 0.721-0.963 | 0.014 |
| | HTN | | 0.722 | 0.644-0.809 | <0.001 |
| | HLD | | 0.88 | 0.800-0.968 | 0.009 |
| COPD | | 1.025 | 0.872-1.204 | 0.765 | |
| COVID19 | | 1.32 | 1.048-1.663 | 0.018 | |
| Bruise | Vaccine | No | | | |
| | | only mRNA vaccine | 1.756 | 1.290-2.391 | <0.001 |
| | | only cDNA vaccine | 1.873 | 1.357-2.586 | <0.001 |
| | | Cross | 1.891 | 1.208-2.962 | 0.005 |
| | Gender | Female | 1.529 | 1.297-1.803 | <0.001 |
| | Age | | 1.011 | 1.005-1.017 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 0.928 | 0.740-1.164 | 0.52 |
| | | High | 1.093 | 0.901-1.326 | 0.367 |
| | CCI | 0 | | | |
| | | 1 | 1.248 | 0.973-1.600 | 0.081 |
| | | 2≤ | 2.095 | 1.627-2.698 | <0.001 |
| | DM | | 0.765 | 0.597-0.980 | 0.034 |
| | HTN | | 1.081 | 0.879-1.329 | 0.459 |
| | HLD | | 1.198 | 0.970-1.478 | 0.093 |
| COPD | | 0.798 | 0.538-1.183 | 0.261 | |

| | | | | | |
|---------------|-----------------|-------------------|-------------|-------------|--------|
| | | COVID19 | 1.032 | 0.428-2.490 | 0.944 |
| Herpes zoster | Vaccine | No | | | |
| | | only mRNA vaccine | 2.195 | 1.988-2.423 | <0.001 |
| | | only cDNA vaccine | 2.465 | 2.225-2.730 | <0.001 |
| | | Cross | 2.894 | 2.539-3.298 | <0.001 |
| | Gender | Female | 1.42 | 1.353-1.490 | <0.001 |
| | Age | | 1.018 | 1.016-1.019 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 1.03 | 0.965-1.100 | 0.367 |
| | | High | 1.056 | 0.997-1.118 | 0.064 |
| | CCI | 0 | | | |
| | | 1 | 1.058 | 0.984-1.138 | 0.129 |
| | | 2≤ | 1.103 | 1.015-1.199 | 0.02 |
| | DM | | 0.9 | 0.832-0.974 | 0.009 |
| | HTN | | 0.902 | 0.848-0.959 | 0.001 |
| | HLD | | 1.232 | 1.158-1.311 | <0.001 |
| COPD | | 1.092 | 0.973-1.225 | 0.136 | |
| COVID19 | | 1.237 | 0.970-1.576 | 0.086 | |
| Alopecia | Vaccine | No | | | |
| | | only mRNA vaccine | 2.304 | 1.815-2.924 | <0.001 |
| | | only cDNA vaccine | 2.244 | 1.695-2.970 | <0.001 |
| | | Cross | 3.413 | 2.520-4.623 | <0.001 |
| | Gender | Female | 1.013 | 0.885-1.161 | 0.847 |
| | Age | | 0.978 | 0.973-0.983 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 0.851 | 0.706-1.025 | 0.089 |
| | | High | 0.955 | 0.810-1.126 | 0.583 |
| | CCI | 0 | | | |
| | | 1 | 1.249 | 0.994-1.571 | 0.056 |
| | | 2≤ | 0.864 | 0.633-1.180 | 0.358 |
| | DM | | 0.765 | 0.566-1.035 | 0.082 |
| | HTN | | 0.711 | 0.569-0.889 | 0.003 |
| | HLD | | 1.306 | 1.059-1.611 | 0.013 |
| COPD | | 0.993 | 0.639-1.543 | 0.974 | |
| COVID19 | | 0.94 | 0.421-2.099 | 0.88 | |
| Warts | Vaccine | No | | | |
| | | only mRNA vaccine | 2.214 | 1.901-2.578 | <0.001 |
| | | only cDNA vaccine | 2.577 | 2.155-3.082 | <0.001 |
| | | Cross | 2.35 | 1.898-2.910 | <0.001 |
| | Gender | Female | 0.842 | 0.771-0.920 | <0.001 |
| | Age | | 0.966 | 0.963-0.969 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 1.02 | 0.899-1.156 | 0.762 |
| | | High | 1.22 | 1.091-1.365 | <0.001 |
| | CCI | 0 | | | |
| | | 1 | 1.268 | 1.093-1.471 | 0.002 |
| | | 2≤ | 1.231 | 1.023-1.482 | 0.028 |
| | DM | | 0.703 | 0.584-0.847 | <0.001 |
| | HTN | | 1.035 | 0.901-1.189 | 0.628 |
| | HLD | | 1.344 | 1.173-1.541 | <0.001 |
| COPD | | 1.068 | 0.819-1.392 | 0.627 | |
| COVID19 | | 1.086 | 0.673-1.750 | 0.736 | |
| | | No | | | |

| | | | | | |
|-------------------|-----------------|-------------------|-------------|--------------|--------|
| Visual impairment | Vaccine | only mRNA vaccine | 2.812 | 0.646-12.247 | 0.168 |
| | | only cDNA vaccine | 6.695 | 1.527-29.361 | 0.012 |
| | | Cross | 2.897 | 0.407-20.626 | 0.288 |
| | Gender | Female | 0.656 | 0.375-1.146 | 0.139 |
| | Age | | 1.007 | 0.984-1.031 | 0.533 |
| | Insurance Level | Low | | | |
| | | Middle | 0.911 | 0.439-1.893 | 0.804 |
| | | High | 0.858 | 0.447-1.649 | 0.647 |
| | CCI | 0 | | | |
| | | 1 | 0.78 | 0.319-1.908 | 0.586 |
| | | 2≤ | 1.352 | 0.548-3.337 | 0.513 |
| | DM | | 0.734 | 0.299-1.801 | 0.5 |
| | HTN | | 1.112 | 0.561-2.203 | 0.761 |
| | HLD | | 1.32 | 0.651-2.677 | 0.441 |
| COPD | | 1.21 | 0.350-4.180 | 0.763 | |
| COVID19 | | | | | |
| Glaucoma | Vaccine | No | | | |
| | | only mRNA vaccine | 1.652 | 1.505-1.813 | <0.001 |
| | | only cDNA vaccine | 1.811 | 1.642-1.997 | <0.001 |
| | | Cross | 1.828 | 1.596-2.093 | <0.001 |
| | Gender | Female | 1.226 | 1.166-1.289 | <0.001 |
| | Age | | 1.012 | 1.010-1.014 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 0.928 | 0.863-0.998 | 0.045 |
| | | High | 1.25 | 1.176-1.329 | <0.001 |
| | CCI | 0 | | | |
| | | 1 | 1.13 | 1.046-1.221 | 0.002 |
| | | 2≤ | 1.174 | 1.075-1.282 | <0.001 |
| | DM | | 0.924 | 0.850-1.003 | 0.059 |
| | HTN | | 0.981 | 0.919-1.046 | 0.553 |
| HLD | | 1.25 | 1.169-1.335 | <0.001 | |
| COPD | | 1.06 | 0.938-1.199 | 0.349 | |
| COVID19 | | 1.234 | 0.957-1.592 | 0.105 | |
| Tinnitus | Vaccine | No | | | |
| | | only mRNA vaccine | 1.783 | 1.513-2.102 | <0.001 |
| | | only cDNA vaccine | 1.85 | 1.553-2.205 | <0.001 |
| | | Cross | 1.494 | 1.157-1.929 | 0.002 |
| | Gender | Female | 1.22 | 1.115-1.334 | <0.001 |
| | Age | | 1.008 | 1.005-1.011 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 1.037 | 0.918-1.171 | 0.563 |
| | | High | 1.011 | 0.907-1.128 | 0.838 |
| | CCI | 0 | | | |
| | | 1 | 1.138 | 0.991-1.308 | 0.067 |
| | | 2≤ | 1.175 | 1.002-1.379 | 0.048 |
| | DM | | 0.886 | 0.761-1.031 | 0.116 |
| | HTN | | 0.921 | 0.818-1.037 | 0.172 |
| HLD | | 1.311 | 1.163-1.478 | <0.001 | |
| COPD | | 1.045 | 0.834-1.310 | 0.701 | |
| COVID19 | | 1.118 | 0.693-1.802 | 0.648 | |
| | Vaccine | No | | | |
| | | only mRNA vaccine | 2.361 | 2.143-2.602 | <0.001 |
| | | only cDNA vaccine | 2.445 | 2.210-2.705 | <0.001 |

| | | | | | |
|--------------------|-----------------|-------------------|-------------|-------------|--------|
| Inner ear disease | | Cross | 2.111 | 1.835-2.428 | <0.001 |
| | Gender | Female | 2.001 | 1.904-2.102 | <0.001 |
| | Age | | 1.015 | 1.013-1.016 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 1.031 | 0.967-1.099 | 0.346 |
| | | High | 1.051 | 0.994-1.112 | 0.083 |
| | CCI | 0 | | | |
| | | 1 | 1.151 | 1.074-1.233 | <0.001 |
| | | 2≤ | 1.176 | 1.085-1.274 | <0.001 |
| | DM | | 0.77 | 0.713-0.832 | <0.001 |
| | HTN | | 0.974 | 0.918-1.035 | 0.399 |
| | HLD | | 1.291 | 1.216-1.371 | <0.001 |
| | COPD | | 1.253 | 1.127-1.393 | <0.001 |
| | COVID19 | | 1.282 | 1.016-1.617 | 0.036 |
| Middle ear disease | Vaccine | No | | | |
| | | only mRNA vaccine | 2.244 | 1.981-2.541 | <0.001 |
| | | only cDNA vaccine | 2.167 | 1.893-2.482 | <0.001 |
| | | Cross | 2.099 | 1.758-2.506 | <0.001 |
| | Gender | Female | 1.207 | 1.130-1.289 | <0.001 |
| | Age | | 0.996 | 0.994-0.999 | 0.002 |
| | Insurance Level | Low | | | |
| | | Middle | 1.038 | 0.949-1.135 | 0.412 |
| | | High | 1.021 | 0.942-1.107 | 0.606 |
| | CCI | 0 | | | |
| | | 1 | 1.251 | 1.128-1.387 | <0.001 |
| | | 2≤ | 1.488 | 1.322-1.673 | <0.001 |
| | DM | | 0.875 | 0.780-0.981 | 0.022 |
| | HTN | | 0.981 | 0.896-1.074 | 0.675 |
| HLD | | 1.114 | 1.016-1.222 | 0.021 | |
| COPD | | 1.236 | 1.057-1.446 | 0.008 | |
| COVID19 | | 1.219 | 0.874-1.701 | 0.244 | |
| Other ear disease | Vaccine | No | | | |
| | | only mRNA vaccine | 2.006 | 1.840-2.186 | <0.001 |
| | | only cDNA vaccine | 1.752 | 1.601-1.917 | <0.001 |
| | | Cross | 1.755 | 1.541-2.000 | <0.001 |
| | Gender | Female | 1.128 | 1.080-1.179 | <0.001 |
| | Age | | 1.021 | 1.019-1.023 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 0.969 | 0.912-1.030 | 0.317 |
| | | High | 1.02 | 0.968-1.076 | 0.459 |
| | CCI | 0 | | | |
| | | 1 | 1.124 | 1.051-1.202 | 0.001 |
| | | 2≤ | 1.196 | 1.109-1.291 | <0.001 |
| | DM | | 0.917 | 0.854-0.983 | 0.015 |
| | HTN | | 0.992 | 0.938-1.049 | 0.77 |
| HLD | | 1.204 | 1.137-1.275 | <0.001 | |
| COPD | | 1.258 | 1.142-1.386 | <0.001 | |
| COVID19 | | 1.218 | 0.974-1.522 | 0.083 | |
| | Vaccine | No | | | |
| | | only mRNA vaccine | 1.84 | 1.259-2.688 | 0.002 |
| | | only cDNA vaccine | 2.197 | 1.501-3.217 | <0.001 |
| | Gender | Female | 0.958 | 0.805-1.140 | 0.627 |

| | | | | | |
|--------------------|-----------------|--------|-------|-------------|--------|
| Peridontal disease | Age | | 1.034 | 1.027-1.041 | <0.001 |
| | Insurance Level | Low | | | |
| | | Middle | 0.822 | 0.651-1.037 | 0.098 |
| | | High | 0.78 | 0.638-0.954 | 0.015 |
| | CCI | 0 | | | |
| | | 1 | 1.364 | 1.052-1.769 | 0.019 |
| | | 2≤ | 1.504 | 1.127-2.008 | 0.006 |
| | DM | | 1.222 | 0.953-1.567 | 0.114 |
| | HTN | | 1.064 | 0.861-1.315 | 0.567 |
| | HLD | | 1.08 | 0.867-1.346 | 0.493 |
| | COPD | | 1.343 | 0.964-1.872 | 0.081 |
| | COVID19 | | 1.863 | 0.926-3.750 | 0.081 |

Supplement table S6. Multivariate logistic regression model of non-fatal immune-related adverse events according to vaccine types

| Disease | Variable | Value | One week | | | Two weeks | | | One month | | | Three months | | |
|--------------------|-----------------|-------------------|-------------|--------------|--------------|-------------|--------------|-------------|-------------|-------------|-------------|--------------|-------------|--------|
| | | | OR | 95% CI | P | OR | 95% CI | P | OR | 95% CI | P | OR | 95% CI | P |
| Endometriosis | Vaccine | No | | | | | | | | | | | | |
| | | only mRNA vaccine | 2.262 | 0.776-6.593 | 0.135 | 1.287 | 0.687-2.409 | 0.431 | 1.227 | 0.836-1.801 | 0.296 | 1.605 | 1.286-2.003 | <0.001 |
| | | only cDNA vaccine | 2.424 | 0.668-8.789 | 0.178 | 1.364 | 0.607-3.063 | 0.452 | 1.14 | 0.688-1.889 | 0.61 | 1.079 | 0.799-1.458 | 0.62 |
| | | Cross | 3.282 | 0.817-13.193 | 0.094 | 1.77 | 0.704-4.450 | 0.225 | 1.752 | 1.000-3.069 | 0.05 | 2.789 | 2.086-3.729 | <0.001 |
| | Gender | Female | | | | | | | | | | | | |
| | Age | | 0.975 | 0.951-0.999 | 0.045 | 0.978 | 0.962-0.995 | 0.013 | 0.974 | 0.964-0.985 | <0.001 | 0.974 | 0.969-0.980 | <0.001 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 0.806 | 0.334-1.943 | 0.631 | 1.094 | 0.547-2.186 | 0.8 | 1.159 | 0.775-1.731 | 0.473 | 1.004 | 0.813-1.240 | 0.967 |
| | | High | 1.074 | 0.495-2.329 | 0.857 | 1.852 | 1.012-3.387 | 0.046 | 1.511 | 1.051-2.174 | 0.026 | 1.291 | 1.068-1.561 | 0.008 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 0.423 | 0.083-2.155 | 0.3 | 0.535 | 0.176-1.626 | 0.27 | 0.816 | 0.466-1.431 | 0.478 | 0.901 | 0.669-1.214 | 0.494 |
| | | 2≤ | 0.293 | 0.031-2.809 | 0.287 | 0.286 | 0.056-1.457 | 0.132 | 0.696 | 0.338-1.430 | 0.324 | 1.056 | 0.743-1.502 | 0.76 |
| | DM | 0.768 | 0.066-8.942 | 0.833 | 1.452 | 0.307-6.859 | 0.638 | 0.977 | 0.447-2.134 | 0.954 | 0.697 | 0.447-1.087 | 0.112 | |
| | HTN | 0.568 | 0.146-2.215 | 0.415 | 0.361 | 0.117-1.115 | 0.077 | 0.701 | 0.401-1.226 | 0.213 | 0.617 | 0.448-0.849 | 0.003 | |
| HLD | 1.339 | 0.460-3.898 | 0.593 | 1.05 | 0.462-2.387 | 0.907 | 1.075 | 0.661-1.749 | 0.77 | 1.02 | 0.780-1.334 | 0.884 | | |
| COPD | 0 | 0.000-0.0 | 0.979 | 0 | 0.000-0.0 | 0.98 | 0.79 | 0.238-2.629 | 0.701 | 0.895 | 0.500-1.603 | 0.71 | | |
| COVID19 | 0 | 0.000-0.0 | 0.988 | 1.957 | 0.272-14.082 | 0.505 | 1.407 | 0.349-5.671 | 0.631 | 1.445 | 0.685-3.044 | 0.333 | | |
| Menstrual disorder | Vaccine | No | | | | | | | | | | | | |
| | | only mRNA vaccine | 1.693 | 1.328-2.159 | <0.001 | 1.782 | 1.499-2.118 | <0.001 | 1.866 | 1.659-2.098 | <0.001 | 2.034 | 1.900-2.177 | <0.001 |
| | | only cDNA vaccine | 1.354 | 0.950-1.930 | 0.093 | 1.544 | 1.209-1.972 | 0.001 | 1.453 | 1.227-1.720 | <0.001 | 1.461 | 1.323-1.612 | <0.001 |
| | | Cross | 2.01 | 1.392-2.902 | <0.001 | 2.579 | 2.021-3.291 | <0.001 | 2.858 | 2.432-3.360 | <0.001 | 2.859 | 2.600-3.143 | <0.001 |
| | Gender | Female | | | | | | | | | | | | |
| | Age | | 0.945 | 0.938-0.952 | <0.001 | 0.945 | 0.941-0.950 | <0.001 | 0.947 | 0.944-0.950 | <0.001 | 0.946 | 0.944-0.948 | <0.001 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 1.02 | 0.817-1.274 | 0.858 | 1.022 | 0.873-1.197 | 0.785 | 1.085 | 0.976-1.206 | 0.133 | 1.086 | 1.022-1.154 | 0.008 |
| | | High | 0.923 | 0.743-1.146 | 0.468 | 1.05 | 0.903-1.220 | 0.527 | 1.043 | 0.942-1.156 | 0.415 | 1.065 | 1.004-1.129 | 0.036 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 1.557 | 1.144-2.120 | 0.005 | 1.365 | 1.093-1.703 | 0.006 | 1.331 | 1.145-1.547 | <0.001 | 1.343 | 1.231-1.464 | <0.001 |
| | | 2≤ | 1.414 | 0.928-2.154 | 0.107 | 1.341 | 0.998-1.801 | 0.051 | 1.216 | 0.990-1.494 | 0.062 | 1.3 | 1.156-1.461 | <0.001 |
| | DM | 1.07 | 0.662-1.728 | 0.783 | 0.848 | 0.593-1.212 | 0.366 | 0.893 | 0.699-1.142 | 0.367 | 0.832 | 0.719-0.962 | 0.013 | |
| | HTN | 0.658 | 0.434-0.996 | 0.048 | 0.666 | 0.498-0.891 | 0.006 | 0.754 | 0.621-0.916 | 0.004 | 0.723 | 0.645-0.810 | <0.001 | |
| HLD | 1.016 | 0.720-1.434 | 0.929 | 1.05 | 0.828-1.331 | 0.689 | 0.932 | 0.791-1.099 | 0.404 | 0.88 | 0.799-0.969 | 0.009 | | |
| COPD | 0.95 | 0.525-1.716 | 0.864 | 0.945 | 0.617-1.448 | 0.796 | 1.03 | 0.777-1.367 | 0.836 | 1.026 | 0.872-1.207 | 0.756 | | |
| COVID19 | 1.258 | 0.521-3.037 | 0.611 | 1.72 | 1.014-2.918 | 0.044 | 1.507 | 1.030-2.207 | 0.035 | 1.324 | 1.048-1.672 | 0.019 | | |
| Bruise | Vaccine | No | | | | | | | | | | | | |
| | | only mRNA vaccine | 4.342 | 1.565-12.041 | 0.005 | 4.199 | 1.828-9.645 | 0.001 | 3.769 | 2.034-6.985 | <0.001 | 1.766 | 1.297-2.404 | <0.001 |
| | | only cDNA vaccine | 5.767 | 2.010-16.543 | 0.001 | 6.26 | 2.680-14.621 | <0.001 | 4.996 | 2.659-9.388 | <0.001 | 1.884 | 1.365-2.600 | <0.001 |
| | | Cross | 2.658 | 0.664-10.645 | 0.167 | 3.515 | 1.219-10.139 | 0.02 | 3.457 | 1.568-7.622 | 0.002 | 1.9 | 1.214-2.976 | 0.005 |
| | Gender | Female | 1.52 | 1.034-2.234 | 0.033 | 1.746 | 1.291-2.360 | <0.001 | 1.634 | 1.290-2.071 | <0.001 | 1.53 | 1.298-1.803 | <0.001 |
| | Age | | 0.991 | 0.976-1.006 | 0.227 | 0.995 | 0.984-1.007 | 0.403 | 1.001 | 0.992-1.010 | 0.853 | 1.011 | 1.005-1.017 | 0.001 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 0.815 | 0.486-1.368 | 0.439 | 0.784 | 0.521-1.179 | 0.243 | 0.968 | 0.703-1.334 | 0.843 | 0.928 | 0.740-1.164 | 0.52 |
| | | High | 0.941 | 0.604-1.468 | 0.789 | 1.008 | 0.717-1.416 | 0.965 | 1.088 | 0.824-1.436 | 0.552 | 1.093 | 0.901-1.326 | 0.366 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 1.115 | 0.627-1.982 | 0.711 | 1.458 | 0.952-2.232 | 0.083 | 1.546 | 1.100-2.173 | 0.012 | 1.248 | 0.973-1.600 | 0.082 |
| | | 2≤ | 1.185 | 0.618-2.274 | 0.609 | 1.951 | 1.238-3.074 | 0.004 | 2.328 | 1.631-3.322 | <0.001 | 2.092 | 1.625-2.694 | <0.001 |
| | DM | 0.823 | 0.448-1.513 | 0.531 | 0.682 | 0.441-1.054 | 0.085 | 0.71 | 0.504-1.000 | 0.05 | 0.765 | 0.597-0.980 | 0.034 | |
| | HTN | 0.834 | 0.514-1.352 | 0.461 | 1.027 | 0.714-1.478 | 0.884 | 0.958 | 0.717-1.281 | 0.774 | 1.081 | 0.879-1.329 | 0.461 | |
| HLD | 2.439 | 1.486-4.002 | <0.001 | 1.911 | 1.311-2.786 | 0.001 | 1.523 | 1.130-2.052 | 0.006 | 1.199 | 0.971-1.480 | 0.091 | | |
| COPD | 0.824 | 0.291-2.329 | 0.715 | 0.559 | 0.243-1.288 | 0.172 | 0.669 | 0.369-1.213 | 0.185 | 0.796 | 0.537-1.181 | 0.258 | | |
| COVID19 | 1.177 | 0.164-8.440 | 0.871 | 1.389 | 0.344-5.599 | 0.644 | 1.285 | 0.412-4.011 | 0.666 | 1.03 | 0.427-2.485 | 0.948 | | |
| Herpes zoster | Vaccine | No | | | | | | | | | | | | |
| | | only mRNA vaccine | 2.385 | 1.635-3.479 | <0.001 | 2.47 | 1.909-3.197 | <0.001 | 2.103 | 1.781-2.483 | <0.001 | 2.211 | 2.002-2.441 | <0.001 |
| | | only cDNA vaccine | 3.116 | 2.109-4.603 | <0.001 | 3.002 | 2.300-3.918 | <0.001 | 2.527 | 2.128-3.001 | <0.001 | 2.483 | 2.242-2.751 | <0.001 |
| | | Cross | 1.873 | 1.066-3.288 | 0.029 | 2.5 | 1.753-3.566 | <0.001 | 2.648 | 2.117-3.313 | <0.001 | 2.915 | 2.557-3.323 | <0.001 |
| | Gender | Female | 1.5 | 1.252-1.796 | <0.001 | 1.518 | 1.345-1.714 | <0.001 | 1.449 | 1.335-1.573 | <0.001 | 1.422 | 1.355-1.492 | <0.001 |
| | Age | | 1.012 | 1.005-1.019 | 0.001 | 1.014 | 1.009-1.018 | <0.001 | 1.016 | 1.013-1.019 | <0.001 | 1.018 | 1.016-1.019 | <0.001 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 1.106 | 0.871-1.405 | 0.409 | 1.053 | 0.896-1.237 | 0.531 | 1.032 | 0.924-1.152 | 0.582 | 1.03 | 0.965-1.100 | 0.368 |
| | | High | 1.017 | 0.818-1.263 | 0.88 | 1.007 | 0.872-1.163 | 0.927 | 1.05 | 0.952-1.158 | 0.329 | 1.056 | 0.997-1.119 | 0.063 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 1.145 | 0.872-1.503 | 0.331 | 1.16 | 0.969-1.390 | 0.106 | 1.156 | 1.023-1.306 | 0.02 | 1.058 | 0.983-1.138 | 0.131 |
| | | 2≤ | 1.062 | 0.771-1.462 | 0.712 | 1.148 | 0.932-1.414 | 0.195 | 1.137 | 0.987-1.310 | 0.075 | 1.101 | 1.013-1.197 | 0.023 |
| | DM | 1.139 | 0.848-1.529 | 0.388 | 0.983 | 0.808-1.195 | 0.864 | 0.924 | 0.808-1.055 | 0.242 | 0.9 | 0.832-0.974 | 0.009 | |
| | HTN | 0.746 | 0.591-0.940 | 0.013 | 0.792 | 0.679-0.924 | 0.003 | 0.886 | 0.799-0.984 | 0.023 | 0.901 | 0.848-0.959 | 0.001 | |
| HLD | 1.228 | 0.971-1.553 | 0.086 | 1.28 | 1.095-1.495 | 0.002 | 1.203 | 1.083-1.337 | 0.001 | 1.234 | 1.160-1.313 | <0.001 | | |
| COPD | 0.965 | 0.609-1.528 | 0.878 | 0.991 | 0.735-1.336 | 0.955 | 1.073 | 0.882-1.304 | 0.483 | 1.09 | 0.971-1.224 | 0.144 | | |
| COVID19 | 1.843 | 0.873-3.889 | 0.109 | 1.41 | 0.797-2.491 | 0.238 | 1.62 | 1.129-2.325 | 0.009 | 1.235 | 0.968-1.575 | 0.089 | | |
| Alopecia | Vaccine | No | | | | | | | | | | | | |
| | | only mRNA vaccine | 2.717 | 1.148-6.432 | 0.023 | 3.202 | 1.654-6.197 | 0.001 | 2.901 | 1.873-4.494 | <0.001 | 2.307 | 1.818-2.928 | <0.001 |
| | | only cDNA vaccine | 2.44 | 0.864-6.892 | 0.092 | 2.647 | 1.229-5.703 | 0.013 | 2.53 | 1.520-4.211 | <0.001 | 2.247 | 1.698-2.974 | <0.001 |
| | | Cross | 3.739 | 1.248-11.198 | 0.018 | 3.721 | 1.602-8.642 | 0.002 | 3.686 | 2.118-6.415 | <0.001 | 3.419 | 2.524-4.632 | <0.001 |
| | Gender | Female | 0.668 | 0.408-1.092 | 0.108 | 0.926 | 0.656-1.306 | 0.66 | 0.832 | 0.659-1.050 | 0.122 | 1.014 | 0.885-1.161 | 0.845 |
| | Age | | 0.972 | 0.954-0.990 | 0.002 | 0.98 | 0.968-0.993 | 0.002 | 0.979 | 0.971-0.988 | <0.001 | 0.978 | 0.973-0.983 | <0.001 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 0.715 | 0.357-1.434 | 0.345 | 0.758 | 0.472-1.217 | 0.252 | 0.947 | 0.685-1.310 | 0.743 | 0.851 | 0.706-1.025 | 0.089 |
| | | High | 1.046 | 0.584-1.873 | 0.879 | 0.9 | 0.597-1.358 | 0.616 | 1.049 | 0.785-1.400 | 0.747 | 0.955 | 0.810-1.126 | 0.584 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 0.815 | 0.305-2.175 | 0.683 | 0.697 | 0.349-1.392 | 0.307 | | | | | | |

| | | | | | | | | | | | | | | |
|--------------------|-----------------|-------------------|-------------|--------------|--------|-------------|--------------|--------|-------------|-------------|--------|-------------|--------------|--------|
| Visual impairment | vaccine | only cDNA vaccine | | | | | | | | | | 6.728 | 1.535-29.489 | 0.011 |
| | | Cross | | | | | | | | | | 2.909 | 0.409-20.710 | 0.286 |
| | Gender | Female | 0.572 | 0.092-3.550 | 0.549 | 0.47 | 0.115-1.920 | 0.293 | 0.498 | 0.209-1.183 | 0.114 | 0.656 | 0.376-1.147 | 0.139 |
| | | Age | 1.078 | 0.975-1.191 | 0.143 | 1.053 | 0.979-1.133 | 0.165 | 1.038 | 1.000-1.078 | 0.051 | 1.007 | 0.984-1.031 | 0.536 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 0.615 | 0.055-6.828 | 0.693 | 0.29 | 0.032-2.606 | 0.269 | 1.085 | 0.405-2.908 | 0.871 | 0.911 | 0.439-1.893 | 0.804 |
| | | High | 0.558 | 0.078-4.012 | 0.562 | 0.584 | 0.145-2.353 | 0.449 | 0.487 | 0.176-1.351 | 0.167 | 0.859 | 0.447-1.649 | 0.647 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 1.299 | 0.067-25.051 | 0.862 | 1.649 | 0.216-12.564 | 0.629 | 0.714 | 0.178-2.863 | 0.634 | 0.78 | 0.319-1.908 | 0.586 |
| | | 2≤ | 2.906 | 0.178-47.312 | 0.454 | 1.456 | 0.151-14.063 | 0.745 | 2.118 | 0.628-7.149 | 0.227 | 1.35 | 0.547-3.333 | 0.515 |
| | | DM | 0.658 | 0.085-5.099 | 0.689 | 1.072 | 0.217-5.307 | 0.932 | 0.559 | 0.167-1.868 | 0.345 | 0.734 | 0.299-1.802 | 0.5 |
| | | HTN | 2.152 | 0.198-23.444 | 0.529 | 2.248 | 0.396-12.774 | 0.361 | 1.398 | 0.519-3.770 | 0.507 | 1.112 | 0.561-2.202 | 0.762 |
| | | HLD | 2.563 | 0.228-28.877 | 0.446 | 2.245 | 0.380-13.252 | 0.372 | 1.022 | 0.373-2.798 | 0.966 | 1.322 | 0.652-2.679 | 0.439 |
| | | COPD | 1.97 | 0.193-20.135 | 0.568 | 3.236 | 0.572-18.311 | 0.184 | 1.993 | 0.528-7.529 | 0.309 | 1.208 | 0.350-4.173 | 0.765 |
| | COVID19 | | | | | | | | | | | | | |
| Glaucoma | Vaccine | No | | | | | | | | | | | | |
| | | only mRNA vaccine | 1.469 | 1.055-2.046 | 0.023 | 1.631 | 1.282-2.074 | <0.001 | 1.405 | 1.204-1.640 | <0.001 | 1.662 | 1.514-1.824 | <0.001 |
| | | only cDNA vaccine | 1.773 | 1.254-2.508 | 0.001 | 1.978 | 1.540-2.540 | <0.001 | 1.604 | 1.363-1.887 | <0.001 | 1.822 | 1.652-2.010 | <0.001 |
| | | Cross | 1.692 | 1.039-2.758 | 0.035 | 2.233 | 1.604-3.110 | <0.001 | 1.814 | 1.451-2.266 | <0.001 | 1.838 | 1.605-2.104 | <0.001 |
| | Gender | Female | 1.221 | 1.017-1.466 | 0.032 | 1.292 | 1.137-1.467 | <0.001 | 1.21 | 1.109-1.320 | <0.001 | 1.227 | 1.167-1.290 | <0.001 |
| | | Age | 1.013 | 1.006-1.021 | <0.001 | 1.014 | 1.009-1.019 | <0.001 | 1.014 | 1.010-1.017 | <0.001 | 1.012 | 1.010-1.014 | <0.001 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 0.996 | 0.756-1.312 | 0.979 | 0.993 | 0.825-1.195 | 0.938 | 0.962 | 0.850-1.090 | 0.545 | 0.928 | 0.863-0.998 | 0.045 |
| | | High | 1.493 | 1.187-1.878 | 0.001 | 1.333 | 1.140-1.559 | <0.001 | 1.213 | 1.091-1.349 | <0.001 | 1.251 | 1.177-1.330 | <0.001 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 1.108 | 0.839-1.462 | 0.471 | 1.111 | 0.915-1.349 | 0.286 | 1.112 | 0.973-1.271 | 0.119 | 1.13 | 1.046-1.221 | 0.002 |
| | | 2≤ | 1.031 | 0.745-1.427 | 0.853 | 1.049 | 0.836-1.315 | 0.679 | 1.079 | 0.925-1.260 | 0.333 | 1.172 | 1.073-1.280 | <0.001 |
| | | DM | 0.803 | 0.589-1.094 | 0.164 | 0.958 | 0.776-1.183 | 0.69 | 0.976 | 0.846-1.125 | 0.735 | 0.924 | 0.850-1.003 | 0.06 |
| | | HTN | 1 | 0.790-1.267 | 0.997 | 1.001 | 0.849-1.179 | 0.992 | 0.931 | 0.832-1.042 | 0.216 | 0.98 | 0.918-1.046 | 0.548 |
| | HLD | 1.304 | 1.027-1.657 | 0.029 | 1.208 | 1.023-1.428 | 0.026 | 1.336 | 1.191-1.498 | <0.001 | 1.252 | 1.171-1.337 | <0.001 | |
| | COPD | 1.028 | 0.647-1.632 | 0.908 | 1.101 | 0.807-1.502 | 0.543 | 1.135 | 0.921-1.399 | 0.235 | 1.058 | 0.936-1.197 | 0.366 | |
| | COVID19 | 2.237 | 1.111-4.504 | 0.024 | 1.464 | 0.807-2.654 | 0.209 | 1.04 | 0.645-1.678 | 0.872 | 1.232 | 0.955-1.590 | 0.109 | |
| Tinnitus | Vaccine | No | | | | | | | | | | | | |
| | | only mRNA vaccine | 2.024 | 1.066-3.843 | 0.031 | 1.616 | 1.057-2.470 | 0.027 | 1.803 | 1.346-2.414 | <0.001 | 1.792 | 1.521-2.112 | <0.001 |
| | | only cDNA vaccine | 1.746 | 0.879-3.470 | 0.112 | 1.494 | 0.949-2.354 | 0.083 | 1.577 | 1.151-2.159 | 0.005 | 1.861 | 1.562-2.217 | <0.001 |
| | | Cross | 0.802 | 0.224-2.877 | 0.735 | 0.795 | 0.345-1.834 | 0.591 | 1.242 | 0.762-2.026 | 0.384 | 1.5 | 1.162-1.937 | 0.002 |
| | Gender | Female | 1.374 | 0.966-1.954 | 0.077 | 1.191 | 0.932-1.521 | 0.163 | 1.177 | 0.999-1.386 | 0.052 | 1.22 | 1.115-1.335 | <0.001 |
| | | Age | 1.013 | 1.000-1.026 | 0.047 | 1.014 | 1.004-1.023 | 0.004 | 1.011 | 1.005-1.017 | <0.001 | 1.008 | 1.005-1.011 | <0.001 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 1.162 | 0.732-1.846 | 0.524 | 1.127 | 0.814-1.561 | 0.47 | 1.101 | 0.884-1.372 | 0.389 | 1.037 | 0.918-1.171 | 0.563 |
| | | High | 0.947 | 0.616-1.456 | 0.805 | 0.946 | 0.700-1.277 | 0.715 | 0.974 | 0.797-1.190 | 0.794 | 1.012 | 0.907-1.129 | 0.835 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 1.096 | 0.640-1.877 | 0.738 | 1.22 | 0.841-1.769 | 0.295 | 1.098 | 0.850-1.418 | 0.473 | 1.138 | 0.990-1.308 | 0.068 |
| | | 2≤ | 1.187 | 0.644-2.187 | 0.582 | 1.318 | 0.862-2.013 | 0.202 | 1.305 | 0.982-1.735 | 0.066 | 1.173 | 0.999-1.376 | 0.051 |
| | | DM | 0.768 | 0.421-1.399 | 0.388 | 0.792 | 0.526-1.193 | 0.265 | 0.792 | 0.599-1.046 | 0.1 | 0.886 | 0.761-1.031 | 0.117 |
| | | HTN | 0.985 | 0.622-1.560 | 0.948 | 1.059 | 0.769-1.459 | 0.726 | 1.01 | 0.813-1.255 | 0.927 | 0.92 | 0.817-1.036 | 0.17 |
| | HLD | 1.201 | 0.755-1.909 | 0.439 | 1.075 | 0.776-1.490 | 0.663 | 1.182 | 0.949-1.472 | 0.136 | 1.313 | 1.164-1.480 | <0.001 | |
| | COPD | 0.87 | 0.341-2.220 | 0.77 | 1.137 | 0.642-2.014 | 0.66 | 0.98 | 0.647-1.483 | 0.922 | 1.043 | 0.832-1.308 | 0.713 | |
| | COVID19 | 1.006 | 0.140-7.201 | 0.996 | 1.444 | 0.462-4.510 | 0.528 | 1.09 | 0.452-2.631 | 0.848 | 1.116 | 0.692-1.799 | 0.654 | |
| Inner ear disease | Vaccine | No | | | | | | | | | | | | |
| | | only mRNA vaccine | 2.146 | 1.554-2.964 | <0.001 | 2.484 | 1.937-3.184 | <0.001 | 2.53 | 2.135-2.997 | <0.001 | 2.379 | 2.159-2.622 | <0.001 |
| | | only cDNA vaccine | 2.346 | 1.671-3.294 | <0.001 | 2.782 | 2.149-3.601 | <0.001 | 2.711 | 2.273-3.234 | <0.001 | 2.464 | 2.227-2.726 | <0.001 |
| | | Cross | 2.282 | 1.454-3.581 | <0.001 | 2.277 | 1.603-3.234 | <0.001 | 2.25 | 1.769-2.861 | <0.001 | 2.125 | 1.847-2.444 | <0.001 |
| | Gender | Female | 2.141 | 1.798-2.551 | <0.001 | 2.019 | 1.784-2.285 | <0.001 | 1.91 | 1.757-2.075 | <0.001 | 2.005 | 1.908-2.106 | <0.001 |
| | | Age | 1.009 | 1.003-1.016 | 0.003 | 1.012 | 1.008-1.017 | <0.001 | 1.013 | 1.010-1.016 | <0.001 | 1.014 | 1.013-1.016 | <0.001 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 1.139 | 0.917-1.416 | 0.239 | 1.107 | 0.943-1.299 | 0.215 | 1.039 | 0.932-1.160 | 0.489 | 1.031 | 0.967-1.099 | 0.346 |
| | | High | 0.989 | 0.810-1.208 | 0.912 | 1.111 | 0.963-1.282 | 0.151 | 1.103 | 1.002-1.214 | 0.046 | 1.051 | 0.994-1.112 | 0.082 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 1.049 | 0.818-1.345 | 0.706 | 1.072 | 0.899-1.278 | 0.437 | 1.09 | 0.967-1.228 | 0.158 | 1.151 | 1.074-1.234 | <0.001 |
| | | 2≤ | 0.937 | 0.694-1.263 | 0.668 | 0.994 | 0.806-1.224 | 0.951 | 1.056 | 0.918-1.215 | 0.444 | 1.174 | 1.084-1.272 | <0.001 |
| | | DM | 0.742 | 0.555-0.992 | 0.044 | 0.771 | 0.630-0.942 | 0.011 | 0.835 | 0.731-0.953 | 0.008 | 0.77 | 0.712-0.832 | <0.001 |
| | | HTN | 1.097 | 0.884-1.360 | 0.401 | 1.041 | 0.895-1.212 | 0.601 | 0.96 | 0.867-1.064 | 0.44 | 0.974 | 0.917-1.035 | 0.397 |
| | HLD | 1.232 | 0.994-1.527 | 0.057 | 1.249 | 1.073-1.454 | 0.004 | 1.294 | 1.168-1.434 | <0.001 | 1.293 | 1.218-1.374 | <0.001 | |
| | COPD | 1.448 | 0.992-2.114 | 0.055 | 1.365 | 1.043-1.785 | 0.023 | 1.476 | 1.240-1.757 | <0.001 | 1.252 | 1.126-1.392 | <0.001 | |
| | COVID19 | 0.658 | 0.212-2.047 | 0.47 | 1.358 | 0.769-2.401 | 0.292 | 1.127 | 0.740-1.716 | 0.577 | 1.281 | 1.014-1.617 | 0.038 | |
| Middle ear disease | Vaccine | No | | | | | | | | | | | | |
| | | only mRNA vaccine | 2.784 | 1.595-4.861 | <0.001 | 2.161 | 1.557-2.998 | <0.001 | 2.169 | 1.741-2.703 | <0.001 | 2.253 | 1.989-2.552 | <0.001 |
| | | only cDNA vaccine | 2.745 | 1.524-4.944 | 0.001 | 1.918 | 1.340-2.744 | <0.001 | 2.069 | 1.629-2.628 | <0.001 | 2.178 | 1.902-2.494 | <0.001 |
| | | Cross | 2.231 | 1.011-4.920 | 0.047 | 1.74 | 1.066-2.840 | 0.027 | 1.93 | 1.401-2.659 | <0.001 | 2.108 | 1.765-2.517 | <0.001 |
| | Gender | Female | 1.147 | 0.884-1.487 | 0.303 | 1.173 | 0.984-1.398 | 0.075 | 1.127 | 1.003-1.267 | 0.045 | 1.208 | 1.131-1.290 | <0.001 |
| | | Age | 1.002 | 0.992-1.012 | 0.684 | 0.994 | 0.988-1.001 | 0.091 | 0.996 | 0.992-1.001 | 0.116 | 0.996 | 0.994-0.998 | 0.002 |
| | Insurance Level | Low | | | | | | | | | | | | |
| | | Middle | 1.132 | 0.793-1.617 | 0.495 | 1.138 | 0.897-1.444 | 0.286 | 1.078 | 0.919-1.264 | 0.357 | 1.038 | 0.949-1.136 | 0.411 |
| | | High | 1.07 | 0.775-1.479 | 0.681 | 1.039 | 0.835-1.292 | 0.734 | 1.041 | 0.901-1.203 | 0.584 | 1.022 | 0.942-1.108 | 0.604 |
| | CCI | 0 | | | | | | | | | | | | |
| | | 1 | 1.338 | 0.901-1.986 | 0.149 | 1.422 | 1.085-1.863 | 0.011 | 1.271 | 1.058-1.526 | 0.01 | 1.251 | 1.128-1.387 | <0.001 |
| | | 2≤ | 1.255 | 0.785-2.005 | 0.343 | 1.719 | 1.267-2.332 | <0.001 | 1.692 | 1.383-2.070 | <0.001 | 1.485 | 1.320-1.671 | <0.001 |
| | | DM | 1.013 | 0.660-1.555 | 0.953 | 0.865 | 0.646-1.156 | 0.327 | 0.819 | 0.672-0.997 | 0.047 | 0.875 | 0.780-0.981 | |

| | | | | | | | | | | | | | | | |
|--------------------|-----------------|--------|--------------|-------------|-------|--------------|-------------|-------|-------------|-------------|-------|-------------|-------------|-------|--|
| Peridontal disease | Insurance Level | Middle | 1.872 | 0.690-5.079 | 0.218 | 1.11 | 0.591-2.087 | 0.745 | 0.742 | 0.497-1.108 | 0.145 | 0.821 | 0.651-1.037 | 0.098 | |
| | | High | 1.758 | 0.696-4.441 | 0.233 | 1.141 | 0.655-1.988 | 0.642 | 0.733 | 0.520-1.033 | 0.076 | 0.78 | 0.638-0.954 | 0.016 | |
| | CCI | 0 | | | | | | | | | | | | | |
| | | 1 | 0.878 | 0.281-2.743 | 0.822 | 1.062 | 0.507-2.225 | 0.874 | 1.303 | 0.817-2.080 | 0.266 | 1.364 | 1.052-1.768 | 0.019 | |
| | | 2≤ | 1.754 | 0.566-5.439 | 0.33 | 2.03 | 0.974-4.231 | 0.059 | 2.153 | 1.332-3.480 | 0.002 | 1.5 | 1.124-2.003 | 0.006 | |
| | | | | | | | | | | | | | | | |
| | DM | 1.275 | 0.426-3.818 | 0.664 | 1.388 | 0.696-2.768 | 0.352 | 1.256 | 0.813-1.940 | 0.305 | 1.222 | 0.953-1.567 | 0.114 | | |
| | HTN | 0.605 | 0.250-1.462 | 0.264 | 1.044 | 0.591-1.845 | 0.882 | 1.177 | 0.811-1.707 | 0.392 | 1.064 | 0.860-1.315 | 0.569 | | |
| | HLD | 0.799 | 0.320-1.998 | 0.632 | 0.729 | 0.403-1.321 | 0.298 | 0.778 | 0.530-1.143 | 0.201 | 1.082 | 0.868-1.348 | 0.483 | | |
| | COPD | 1.716 | 0.472-6.235 | 0.412 | 0.833 | 0.292-2.376 | 0.732 | 1.02 | 0.552-1.886 | 0.95 | 1.341 | 0.962-1.869 | 0.083 | | |
| | COVID19 | 3.402 | 0.463-25.001 | 0.229 | 3.277 | 0.802-13.393 | 0.098 | 2.743 | 1.015-7.411 | 0.047 | 1.858 | 0.923-3.740 | 0.083 | | |